 
This document is a confidential communication of Mati Therapeutics Inc.  Acceptance of this document 
constitutes an agreement by the recipient that the contents will not be disclosed to any unauthorized personnel 
without the prior written authorization of Mati Therapeutics Inc.  
  
Mati Therapeutics Inc.  
101 Colorado St., Suite 2409  
Austin, TX  787 01 
  
  
CONFIDENTIAL  
The following contains confidential, proprietary information which is  
the property of Mati Therapeutics  
    
PROTOCOL:  CLINICAL STUDY TGLA -2021- 01 
    
A 90-Day, Open- Label, Multi- Site, Pilot Study Evaluating 
the Safety and Intraocular Lowering Effect of Delivering 
Travoprost using a Punctal Plug Delivery System 
(Evolute®) in Subjects with Elevated Intraocular Pressure 
 
  
 
Protocol Version 3:  08 April 2022 
Travoprost Punctal Plug Delivery System, 166 µg/L67 
IND 114300 
 
 
 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  2 Mati Therapeutics Inc. - CONFIDENTIAL  
 TABLE OF CONTENT S 
 
PROTOCOL APPROVAL  .....................................................................................................6  
ABBREVIATIONS AND DE FINITIONS  .............................................................................9  
STUDY SYNOPSIS  ...............................................................................................................10  
1 KEY ROLES  ..............................................................................................................16  
2 INTRODUCTION: BACKGROUND AND INFORMATION AND SCIENTIFIC 
RATIONALE  .............................................................................................................17  
2.1 Background Information ..............................................................................................17  
2.2 Rationale  ......................................................................................................................18  
2.3 Potential Risks and Benefits ........................................................................................19  
2.3.1  Known Potential Risks .................................................................................................19  
2.3.2  Known Potential Benefits ............................................................................................20  
3 OBJECTIVES AND PURPO SE ...............................................................................20  
4 STUDY DESIGN AND ENDPOINTS  ......................................................................20  
4.1 Description of the Study Design ..................................................................................20  
4.2 Study Endpoints  ...........................................................................................................21  
4.2.1  Primary Endpoint .........................................................................................................21  
4.2.2  Other Data Endpoints ...................................................................................................21  
4.2.3  Safety Endpoints  ..........................................................................................................21  
5 STUDY ENROLLMENT AND WITHDRAWAL  ..................................................21  
5.1 Study Population ..........................................................................................................21  
5.2 Study Inclusion/Exclusion Criteria  ..............................................................................21  
5.2.1  Study Screening Phase Criteria  ....................................................................................21  
5.2.2  Washout Phase - Criteria  .............................................................................................24  
5.2.3  Study Treatment Phase Criteria  ...................................................................................24  
5.3 Strategies for Recruitment and Retention  ....................................................................25  
5.4 Study Subject Withdrawal or Termination Criteria  .....................................................25  
5.4.1  Reasons for Termination, Discontinuation or Disqualified .........................................26  
5.4.2  Reasons for Termination ..............................................................................................26  
5.4.3  Handling of Study Subject Termination, Discontinued or Disqualified ......................27  
5.5 Premature Termination or Suspension of Study or Study Site ....................................27  
6 STUDY AGENT AND PROCEDURES ...................................................................28  
6.1 Study Treatment ...........................................................................................................28  
6.1.1  Route of Administration  ..............................................................................................28  
6.1.2  Formulation, Appearance, Packaging and Labeling ....................................................28  
6.1.3  Product Storage and Stability.......................................................................................30  
6.1.4  Starting Dose  ................................................................................................................30  
6.1.5  Preparations and Insertion of a Travoprost Evolute ....................................................30  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  3 Mati Therapeutics Inc. - CONFIDENTIAL  
 6.1.6  Instructions for Study Subjects after Travoprost Evolute Insertion .............................31  
6.1.7  Procedure for the Removal of a Travoprost Evolute (Appendix E for detailed 
instructions)..................................................................................................................31  
6.1.8  Unable to Insert/Extruded/Lost Travoprost Evolute® ..................................................32  
6.1.9  Duration of Therapy .....................................................................................................32  
6.2 Study Plug Accountability Procedures ........................................................................33  
7 STUDY PROCEDURES AND SCHEDULE  ...........................................................33  
7.1 Protocol Amendments ..................................................................................................33  
7.2 Study Procedures/Evaluations .....................................................................................33  
7.2.1  Study Specific Procedures ...........................................................................................33  
7.2.2  Standard of Care Procedures  ........................................................................................35  
7.3 Laboratory Procedures/Evaluations .............................................................................35  
7.4 Study Visit Phases/Schedule  ........................................................................................35  
7.4.1  Visit 1 - Screening Phase (Qualification Visit) ............................................................35  
7.4.2  Washout Phase (Six-week duration) ............................................................................36  
7.4.3  Treatment Phase (Visits 2, 3, 4, 5, 6 & 7) ....................................................................36  
7.5 Unscheduled Visit ........................................................................................................42  
7.6 Early Ex it Visit (Disqualified, Discontinued or Terminated Study Subject)  ...............42  
7.7 Emergency Anaphylactic or Overdose Procedures, Dose Modifications ....................42  
7.8 Concomitant Medication  ..............................................................................................43  
7.8.1  Pre-Study Concomitant Medication Use .....................................................................43  
7.8.2  Concomitant Medication Use during Study .................................................................43  
7.9 Prohibited Medications, Treatments and Procedures ...................................................43  
7.9.1  Prohibited Medications ................................................................................................43  
7.9.2  Prohibited Treatments  ..................................................................................................44  
7.9.3  Prohibited Procedures ..................................................................................................44  
7.10  Rescue Medication(s) ...................................................................................................44  
7.10.1  Administration of a Rescue Medications .....................................................................44  
8 ASSESSMENT OF SAFEETY .................................................................................44  
8.1 Safety Variables  ...........................................................................................................44  
8.2 Definitions ....................................................................................................................45  
8.2.1  Adverse Event  ..............................................................................................................45  
8.2.2  Serious Adverse Event .................................................................................................45  
8.3 Adverse Event Descriptions .........................................................................................46  
8.3.1  Intensity........................................................................................................................46  
8.3.2  Relationship  to Study Treatment  .................................................................................46  
8.4 Follow-up for Adverse Event Definitions....................................................................47  
8.5 Pregnancy Follow -up ...................................................................................................47  
8.6 Reporting of Technical Complaint...............................................................................47  
8.6.1  Definitions ....................................................................................................................47  
8.6.2  Reporting of Technical Complaints .............................................................................47  
8.6.3  Punctal Plug Delivery System Serious Adverse Events and Technical Complaints ...48  
8.6.4  Anticipated Adverse Event ..........................................................................................49  
8.7 Reporting Procedures ...................................................................................................49  
8.7.1  Adverse Event Reporting .............................................................................................49  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  4 Mati Therapeutics Inc. - CONFIDENTIAL  
 8.7.2  Serious Adverse Event Reporting ................................................................................49  
8.7.3  Unanticipated Problem Reporting................................................................................51  
8.7.4  Events of Special Interest .............................................................................................51  
8.8 Halting Rules  ...............................................................................................................51  
8.9 Safety Overs ight...........................................................................................................51  
9 CLINICAL MONITORING  .....................................................................................51  
10 STATISTICAL CONSIDERATIONS  .....................................................................53  
10.1  Statistical and Analytical Plans  ....................................................................................53  
10.2  Statistical Hypotheses  ..................................................................................................53  
10.3  Analysis of Datasets  .....................................................................................................53  
10.4  Description of Statistical Methods  ...............................................................................53  
10.4.1  General Approach  ........................................................................................................53  
10.4.2  Analysis of Primary Study Variable  ............................................................................53  
10.4.3  Other Data Endpoints ...................................................................................................53  
10.4.4  Safety Analyses  ............................................................................................................54  
10.4.5  Adherence and Retention Analyses  .............................................................................54  
10.4.6  Baseline Descriptive Statistics  .....................................................................................54  
10.4.7  Planned Interim Analyses ............................................................................................54  
10.4.8  Tabulation of Individual Response Data......................................................................54  
10.4.9  Exploratory Analyses ...................................................................................................54  
10.5  Sample Size  ..................................................................................................................55  
10.6  Measures to Minimize Bias  .........................................................................................55  
10.6.1  Enrollment....................................................................................................................55  
10.6.2  Evaluation of the Success of Blinding/Masking Treatment ........................................55  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DAT A/DOCUMENTS  .................55  
11.1  Source Documentation .................................................................................................55  
11.2  Access and Retention of Study Records ......................................................................56  
11.3  Subject Confidentiality  ................................................................................................56  
11.4  Case Report Form Completion  ....................................................................................56  
11.5  Investigator Study Summary ........................................................................................57  
12 QUALITY ASSURANCE AND QUALITY CONTROL  .......................................57  
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ..............................................57  
13.1  Ethical Standard  ...........................................................................................................57  
13.2  Institutional Review Board  ..........................................................................................58  
13.3  Informed Consent Process ...........................................................................................58  
13.3.1  Consent Procedures and Documentation  .....................................................................58  
13.3.2  Other Informational Documents Provided to Participants ...........................................58  
13.4  Participant and Data Confidentiality  ............................................................................59  
13.4.1  Research Use of Stored Human Samples, Specimens or Data  ....................................59  
14 DATA HANDLING AND RE CORD KEEPING  ....................................................59  
14.1  Data Collection and Management Responsibilities  .....................................................59  
14.2  Study Records Retention..............................................................................................59  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  5 Mati Therapeutics Inc. - CONFIDENTIAL  
 14.3  Protocol Deviations ......................................................................................................59  
14.4  Publications and Data Sharing Policy ..........................................................................59  
15 LITERATURE REFERENCE S ...............................................................................61  
16 APPENDICES  ............................................................................................................61  
 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  7 Mati Therapeutics Inc. - CONFIDENTIAL  
 STATEMENT OF COMPLIA NCE  
Mati Therapeutics Inc. Protocol TGLA -2021- 01 
A 90- Day, Open -Label, Multi -Site, Pilot Study Evaluating the Safety and Intraocular  
Lowering Effect of Delivering Travoprost using a Punctal Plug Delivery System  
(Evolute®) in Subjects with Elevated Intraocular Pressure  
Protocol Version 3:  08 Apr 2022 
Sponsor and Medical Monitor Approval: 
 
 
Signature:   ___________________________________________ Date:  _____________  
Dr. Robert Williams, M.D., Medical Monitor 
Investigator Agreement: 
I have read this protocol in its entirety and agree to:  
a. Implementing and conducting this study in strict compliance with this agreement; the protocol; 
ICH guidelines for Good Clinical Practices and all other applicable regulatory requirements.   
b. No deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), except where necessary to eliminate an immediate hazard(s) to the study participants.  
c. Obtain written Informed Consent (IC) that is IRB/IEC approved, from each prospective study subject at screening and prior to any study specific examination/test.  
d. Obtain authorization for use/disclosure of health information (HIPAA authorization) 
e. Maintain reliable study device dispensing log, receipt and return shipping records, and to store 
study supplies in a secure, locked facility accessible only to authorized study personnel  
f. Maintain adequate and accurate source documents in accordance with Food and Drug Administration (FDA) regulations (e.g., CRFs, consent forms, AE/SAE and ADE/SADE 
forms, IRB/IEC documentation, and study supply records). Keep source documentation for the 
maximum period of time permitted by the hospital, institution, or private practice.  In addition, 
will notify the Sponsor immediately if any documents are to be destroyed, transferred to a 
different facility or owner 
g. Maintain all information supplied by Mati Therapeutics Inc. in confidence and, when this information is submitted to an independent IRB/IEC or any other group, it will be submitted with a designation that the material is confidential.  
h. Attempt to complete the study within the time designated .  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  8 Mati Therapeutics Inc. - CONFIDENTIAL  
  
By signing this “STATEMENT OF AGREEMENT”, the Investigator grants permission to 
personnel from the Sponsor, its representatives, third parties and appropriate regulatory authorities for on -site monitoring and review of all appropriate study documentation, as well as on- site review 
of the procedures employed in data collection, where clinically appropriate. 
 
    Investigator Signature:   _____________________________________Date:  ___________  
“TYPE/Print Name of INVESTIGATOR”  
     Acknowledged By/Sponsor’s Representative Signature:   
  Representative Signature:   ___________________________________Date:  ___________  
“TYPE/Print Name of Representative”  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  9 Mati Therapeutics Inc. - CONFIDENTIAL  
 ABBREVIATIONS AND DE FINITIONS  
ADE  Adverse Device Effect  
AE Adverse Effect  
BCDVA  Best-Corrected Distance Visual Acuity  
BP Blood Pressure 
BT Body Temperature (Fahrenheit)  
CDC  Center for Disease Control  
CRA  Clinical Research Associate  
CFR  Code of Federal Regulations  
CRF  Case Report Form  
CRC  Clinical Research Coordinator 
Evolute® Punctal Plug Delivery System 
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form 
ICH  International Conference on Harmonisation  
ICH E6  International Conference on Harmonisation Guidance for Industry Good 
Clinical Practice: Consolidated Guidance  
IEC Independent Ethics Committee  
IOP Intraocular Pressure 
IRB Investigational Review Board  
ITT Intent- to-treat 
MedDRA  Medical Dictionary for Regulatory Activities  
mmHg  Millimeters of Mercury  
NCR  No Carbon Required  
NDE  Non-drug eluting  
NSR  Non-Significant Risk  
PP Per Protocol 
QC  Quality Control  
OH  Ocular Hypertension  
OTC  Over -the-Counter 
POAG Primary Open -Angle Glaucoma  
PPDS  Punctal Plug Delivery System  
SADE  Serious Adverse Device Event  
SAE  Serious Adverse Event  
Study Subject An individual that has signed a HIPAA and study consent form 
Subject  Individual being considered for enrollment in to the study  
UP Unanticipated Problem  
VA Visu al Acuity  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  10 Mati Therapeutics Inc. - CONFIDENTIAL  
 STUDY SYNOPSIS  
STUDY PROTOCOL NUMBER:  TGLA -2021-01 
STUDY PROTOCOL TITLE: A 90-Day, Open -Label, Multi -Site, Pilot Study Evaluating the 
Safety and Intraocular Lowering Effect of Delivering Travoprost using a Punctal Plug Delivery 
System (Evolute®) in Subjects with Elevated Intraocular Pressure 
SPONSOR : Mati Therapeutics Inc.  
INVESTIGATIONAL PRODUCT, OPEN- LABEL: The Travoprost Evolute (Travoprost 
Punctal Plug Deliver y System)  is an L -shaped, silicone punctal plug with a drug eluting core that 
contains travoprost (active).  The Travoprost Evolute is pre -loaded onto a disposable inserter  tip 
and individually packaged and sterilized to prevent contamination. The Travoprost Evolute is 
stored at  refrigerated temperature.   
Travoprost Evolute System  
 
NUMBER OF SITES : Up to 8 sites within the U.S.A.  
STUDY POPULATION: Up to 30 qualified male or female subjects (~ 30 qualified  eyes) who 
have given HIPAA and informed consent, have met all screening, washout  and treatment phase 
inclusion/exclusion criteria of the study, will be enrolled and will receive a Travoprost Evolute 
inserted in to the lower punctum of each eye.  
STUDY OBJECTIVE : Using a punctal plug delivery system ( Evolute ) to deliver a hypotensive 
(travoprost) drug to the eye, evaluate the safety and ocular effects of a Travoprost Evolute system 
in reducing intraocular pressure in individuals diagnosed with OAG or OH. STUDY DESIGN: This is a pilot, open- label, multi- center clinical study.  Each potential subject 
that has given HIPAA and informed consent and has meet all screening inclusion/exclusion criteria 
will undergo a six-week washout  phase where they will discontinue the use of their topical 
hypotensive medication. In ad dition, during the washout phase, each potential study subject will 
also discontinue the use of all prohibited systemic medications. 
After the six-week washout , each potential subject will return for a baseline visit (Visit 2) . 
Investigators will verify that a potential subject has discontinued the use of their topical 
hypotensive medication(s) and all their prohibited systemic medications for the last 6 weeks. In 
addition, each subject will have discontinued the use of all other ocular drops, gels or ointments 
24 hours prior to the visit (Visit 2) and continues to meet all screening and washout criteria. After 
completing the baseline examination, each potential subject that meet all baseline Drug Core
Polymer SleeveCyanoacrylate filmDrug Insert Slot
Drug Insert Punctum PlugFinal Drug Product
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  11 Mati Therapeutics Inc. - CONFIDENTIAL  
 inclusion/exclusion for the treatmen t phase of the study will have his/her lower puncta of each eye 
inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the 
investigator’s office the next day , seven, 28, 60 and 90 after the insertion of their plugs  for foll ow-
up examinations. 
SUBJECT SELECTION : The following are inclusion and exclusion criteria for a prospective 
study subject 
i. Screening Phase  
a. INCLUSION Criteria : The following are requirements a subject must meet in order to be 
considered for inclusion into the screening phase of the study:  
1. Male or female subject, 18 years of age or older at the time of the screening examination 
and has been diagnosed with bilateral OAG or OH 
2. A subject must be able and willing to read, comprehend and give authorization for 
Use/Disclosure of Health Information (HIPAA) and informed consent 
3. A subject must not have taken any ocular hypertension medication(s) within the last 12 hours of the screening visit unless in the opinion of the screening physician it poses an undue risk. 
4. A subject must be willing to have the lower puncta of each eye inserted with a study 
plug 
5. A subject’s screening visit (pre -washout) IOPs, measured between 8:00 and 10:00 AM, 
is less than 22 mmHg in both eyes 
6. A subject IOPs are currently controlled ( < 22 mm Hg) with a topical prostaglandin or 
in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.), in both eyes for at least one month 
7. A subject must be willing to comply with study instructions and agree to complete the 
entire course of the study 
8. A subject must agree to make all office appointments and have all office visits occur between 8:00 and 10:00 AM 
9. Women of child- bearing potential must not be pregnant or lactating, must have a 
negative pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal (“patch”), implant or injected contraceptives; tubal ligation; or barrier methods with  spermicide  
10. A subject has a Best-Corrected Distance (Glasses) , pinhole visual acuity of 20/100 
(Snellen) or better in both eyes 
11. A subject  has documented perimetry results within the last 6 months prior to the 
Screening Visit for both eyes 
NOTE:  If perimetr y measurement are older than 6 months, perform automated 
perimetry at the screening visit 
12. A subject  has documented central corneal thickness measurements between >500 µm 
and <600 µm in both eyes 
NOTE:  if corneal thickness data is not available, measure corneal thickness of each eye using pachymetry at the screening visit  
b. EXCLUSION Criteria : If any of the below criteria apply to a potential study subject, the 
subject does not qualify for enrollment into the screening phase of the study: 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  12 Mati Therapeutics Inc. - CONFIDENTIAL  
 1. A subject with a history of non- response to topical prostaglandin eye drops for 
OAG/OH  
2. A subject with angle -closure glaucoma, neovascular glaucoma, traumatic glaucoma or 
iridocorneal endothelium syndrome in either eye 
3. A subject with a known sensitivity to travoprost, fluor escein, topical anesthetic, 
silicone, any inactive ingredient of the Travoprost Evolute® or any other products 
required for study procedures 
4. A subject with > 0.9 vertical cup or completely notched optic nerve head rim in either 
eye 
5. A subject with any funct ionally significant visual field loss or progressive field loss 
within the last year in either eye  
6. A subject with a history of complications, AEs, trauma or disease in the nasolacrimal 
area, whether or not it was due to punctal plug wear, including but not limited to 
dacryocystitis, inflammation or canaliculitis in either eye  
7. A subject with a history of intolerance to punctal plugs or a known sensitivity to any 
inactive ingredient of the punctal plug, silicone, topical anesthetic, or any other products required for the study 
8. A subject with structural lid abnormalities (i.e., ectropion, entropion) in either eye 
9. A subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, 
meibomianitis) that requires medical treatment  
10. A subject wi th any clinically significant (moderate or severe) lid, conjunctival or 
corneal findings in either eye at the screening visit  
11. A subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, 
uveitis, herpes keratitis) in either eye  
12. A subject who would require the use of any ocular medication(s), an over -the-counter 
drop(s), ointment(s) or gel(s), other than the study hypotensive medication(s) in either eye during the study period 
13. A subject who has had any ophthalmic surgical procedur es (i.e., glaucoma laser, 
minimally invasive glaucoma surgery, cataract, refractive, etc.) in either eye within the last six months or will require ophthalmic surgery before completing the study  
14. A subject with a history of penetrating keratoplasty in eithe r eye  
15. A subject requiring the use of a contact lens in either eye at any time during the study 
period 
16. A subject with advanced diabetic retinopathy, branch retinal vein occlusion or central 
retinal vein occlusion in either eye 
17. A subject with a history of macular edema in either eye  
18. A subject currently on any systemic medication [i.e., beta -blocker, carbonic anhydrase 
inhibitors, corticosteroids (including dermal), etc.] that may have an effect on the subject's IOP, or who will require its use during the study period  
NOTE : An inhaled steroid, systemic beta -blocker or β- adrenoceptor 
antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months  
19. A subject with an uncontrolled systemic disease or a medical condition that may 
increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e.g., 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  13 Mati Therapeutics Inc. - CONFIDENTIAL  
 autoimmune disease if the subject is on chronic medications and has ocular 
involvement; host-versus- graft disease)  
20. A subject currently participating or has participated within the last 30 days prior to the 
start of this study in a drug, device or other investigational re search study.  
ii Washout Phase 
After the screening phase (process), each subject meeting all screening inclusion/exclusion criteria must be willing to: 
1. DISCONTINUE  the use of  his/her  topical hypotensive medication(s) for the next six-
weeks and not to use his/her hypotensive medication for the duration of the study 
2. DISCONTINUE  the use of  all other ocular drops, gels or ointments that have not been 
prescribed by the investigator, 24 hours prior to Visit 2 and  for the duration of the study  
3. DISCONTINUE  the use of  all systemic medication that are PROHIBITED by the protocol 
for the duration of the study. Systemic medication(s) being used by a subject at the 
Screening visit and is permitted by the protocol, may continue the medication(s), however the concentration and dosing  frequency  must remain the same throughout 
the washout and treatment phases of the study. 
iii. Treatment Phase  
a. INCLUSION Criteria : After the washout phase, t he following are requirements a subject 
must meet in order to be considered for enrollment into the treatment phase of the study:  
1. After the six-week washout  phase, the subject continues to meet all screening and 
washout inclusion/exclusion study criteria  
2. After the six-week washout  phase, subject’s Baseline (Visit 2) IOP measured between 
8:00 and 10:00 AM, is  between ≥ 23 and < 34 mmHg in at least one  eye 
3. Subject’s Baseline ( Visit 2, morning average)  IOP is > 5 mmHg from the subject’s 
SCREENING (pre -washout) IOP  in at least one  eye whose Baseline IOP is between 
> 23 and < 34 mmHg 
4. Investigator is able to dilate the lower puncta of each eye to 1.0 mm, and insert a study 
plug into each puncta. 
b. EXCLUSION Criteria : If any of the below criteria apply to a study subject that has 
completed the washout period, the subject does not qualify for enrollment into the treatment phase of the study : 
1. A subject who no longer meets all the screening and washout study criteria 
2. A subject who cannot be successfully inserted with a Travoprost Evolute® in the  
lower puncta of each eye, even if only one eye qualifies for enrollment. 
STUDY VARIABLES : The following will be performed and/or recorded during the course of the 
study: 
a. Obtain written HIPAA and Informed Consent 
b. Verify a subject has not used any hypotensive ocular drops within the last 12 hours prior to 
the screening visit or at any time during the washout or treatment phases of the study  
c. Record any changes in the subject's use of any concomitant medications or ocular drops, gels or ointments during the course of the study 
d. Record subject’s  demographic data and medical history for past 6 months 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  14 Mati Therapeutics Inc. - CONFIDENTIAL  
 e. Perform a urine pregnancy test on a female subject of child -bearing potential at the ir screening 
and last study visits 
f. Measure subject’s temperature, heart rate and blood pressure  
g. Record subject’s Bes t-Corrected (Glasses) Distance or Pinhole Visual Acuity  
h. Verify documented automated perimetry results have been measured in the last 6 months 
NOTE:  If perimetry measurement are older than 6 months, perform automated perimetry 
at the screening visit. 
i. Verify  corneal thickness measurements are documented in the subject’s chart  
NOTE:  if corneal thickness data is not available, measure corneal thickness of each eye 
using pachymetry at the screening visit  
j. Perform a slit -lamp examination of each eye  
k. Perform a non -dilated fundus exam of each eye, including the evaluation of the lens 
l. Perform IOP measurements of each eye  
m. Dilate lower punctum to 1.0 mm and insert a study plug  in to the lower puncta of each eye 
n. Evaluate the study plug position in each eye using the slit- lamp  
o. Record any Adverse Events/Adverse Device Events . 
Study Duration:  The approximate study duration is 12 months. Study projected to start 1st 
Qtr. 2021 
Study Outcome  Endpoint :  
Primary Endpoint: Change in IOP from the baseline visit to Day s seven, 28, 60 and 90. 
Other Collected Data: Changes in IOP and percent change between the screening and the baseline 
visits (after washout phase, prior to insertion of any Travoprost Evolute®), 
percent of screened patients that qualified for washout phase, percent of patients that entered the washout phase that qualified for the treatment phase, enrollment rates (rates in to each phase of the study), number and percent of study subjects whose IOPs were >34 mmHg at Visit 2, number 
and percent of eyes that extruded a study plug, number of eyes investigators were unable to dilate or insert a study plug, listing of reasons why patients 
failed to qual ify. 
Safety Endpoint Safety variables include any  reported AEs/SAEs. Safety variables will also 
include any clinically significant changes in IOP, BCDVA, slit- lamp 
findings, ocular tearing and comfort, blood pressure, heart rate, temperature, Travoprost Evolute®  inspections/extrusions .  Safety analyses w ill be 
performed on all subjects who enter the washout phase of the study. Subjects that were inserted with a study plug will be subgrouped and summarized separately.  
Sample Size   
     Determination: Since this is a pilot study, no formal sample size estimation will be  
performed .
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  15 Mati Therapeutics Inc. - CONFIDENTIAL  
 Schedule of Assessments, Events  
Visit Examination Parameters   Visit 1 
Screening   Visit 2  
(Day 0)   Visit 3  
(Day1)   Visit 4  
(Day 7)   Visit 5  
(Day28)   Visit 6  
(Day 60)   Visit 7  
(Day 90)  
Inform ed Consent/HIPAA                    
Medical Hx (past 6 months)/Demographic Data             A           
Urine Pregnancy Test  (Only women of childbearing potential )      B                B 
Concomitant Med Use                                            
BT ( temperature ), BP ( blood pressure ), HR ( heart rate )                                           
Evaluate study plug position prior to any eye exam         *                               
Best-Corrected Distance (Glasses) or Pinhole VA                                            
Automated Perimetry  (Not required  if measured in last 6 months )                   
Pachymetry  (Not required  if documented in patient’s chart )                   
Slit-Lamp Examination                                            
IOP ( Goldmann ) Evaluation  (To be measured between 8 and 10 am )                                           
Non-Dilated Fundus Examination  (Include evaluation of the LENS )                   
Begin Six -Week Washout  (D/C all topical drops, gels, ointments )                   
Punctal Size Evaluation, Dilation of Lower Puncta                    
Insertion of Punctal Plugs                    
**Punctal Plug Extrusion          C     C,D     C,D     C,D       
Removal of Punctal Plugs after eye exam completed                    
Adverse Event/Adverse Device Event Recording                                        
               
Keys to Abbreviations : 
A = Verify no change in medical history, subject still meets all study inclusion/exclusion criteria  
B = If performed at the screening visit, must be performed when subject exit the study  
C = In a subject where both eyes qualified at Visit 2, i f a plug is extruded in one eye, plug is to be replaced  and subject continues  in the study  
D = In a subject where only one eye qualified at Visit 2, i f the plug is extruded in the qualified  eye, the subject will be DISCONTINUED and replaced.  In a subject where both eyes qualified, i f a 
plug is extruded in one eye, then extruded again or in the fellow eye, the subject will be DISCONTINUED and replaced  
* = Plug position evaluated after eye exam and plug insertion  
 = If subject EXITs the study after visit 2, but before visit 7, subject must return to Investigator’s office to have plugs removed  
 
Body Temperature:  Temperature maybe taken using a non -contact (Infrared) thermometer or orally. Oral temperatures should not be taken within five minutes of ingestion of any food or dri nk 
Heart Rate:  Heart rate taken in the sitting position after subject has rested for 5 minutes.  Recorded values can be obtained electronically (automated) or manually (observed for 30 seconds or more)  
Blood  Pressure:  Blood pressure, taken in the sitting position after subject has rested for 5 minutes.  Recorded values can be obtained electronically (automated) or manually  
Plug Position Evaluation:  Position of the plug will be evaluated as either:  Normal , Present but requires adjustment,  Extruded/Recovere d, Extruded/Lost , Other  
Slit-Lamp Exam:  Evaluation will include the Lids (Upper & Lower), Conjunctiva (Bulbar & Palpebral) and the Cornea.  SL Findings will be graded on a 5-point scale:    
     0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe  
IOP Evaluation:  Goldmann applanation tonometry will be used for measuring IOP.  Just prior to the start of the study, the tonometer should be calibrated.  IOP of each eye will be measured twice,  
     alternating between the eyes.  The average of the two measurements will be used for analysis.  However, if there is a > ± 3 mmHg difference between the 1st and 2nd measurement  
     for an eye, a 3rd measurement will be taken and the average of the two closest values of the three will be used for analysis for that eye.  
 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  16 Mati Therapeutics Inc. - CONFIDENTIAL  
  
1 KEY ROLES  
Sponsor : Mati Therapeutics Inc. (Headquarters)  
101 Colorado, Apt 2409 
 Austin, TX 78701 
 512 329-6360 
 
Sponsor Personnel : 
Clinical Trial Deepank Utkhede  
      Coordinator: Chief Scientific Officer  
 Mati Therapeutics Canada Inc. (R&D Branch) 
 201-4475 Wayburne Drive 
 Burnaby, BC V5G 4X4 
 Cell: 778.991-3301 Fax:  604 637-8747 
 dutkhede@matitherapeutics.com  
 
Study Monitor/  Daniel Schwob  
Biostatistician: D’Ellis Group, Inc. 
 26741 Portola Pkwy, Ste 1E 717 
 Foothill Ranch, CA 92610 
 Office :  949.916-2800 Cell:  949.735-1320 
 dschwob@dellisgroup.com  
 
Regulatory  Caroline Stokl, Ph.D., 
Specialist: Consultant, Regulatory Affairs 
 201-4475 Wayburne Drive 
 Burnaby, BC V5G 4X4 
 Office : 604.983-9103 
 cstokl@matitherapeutics.com 
 
Medical Monitor: Robert Williams, MD  
 89 Wilks Way  
 Friday Harbor, WA 98250 
 Office : 360.378-7916 Cell: 360.298-5325 
 iopdoc1@gmail.com   
 
Emergency  24-hour Adverse Event /Adverse Device Event   
FAX Number:  FAX : 360.282-6871 
 Robert Williams, MD  
 Office : 360.378-7916 Cell: 360.298-5325 
 Deepank Utkhede  
 Cell: 778.991-3301 Fax:  604 637-8747 
 Daniel Schwob  
 Office : 949.916-2800 Cell: 949.735-1320 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  17 Mati Therapeutics Inc. - CONFIDENTIAL  
 2 INTRODUCTION: BACKGROUND AND INFORMATION AND SCIENTIFIC 
RATIONALE  
This study will be conducted in compliance with the protocol, International Conference on 
Harmonization (ICH), Good Clinical Practice (GCP) guidelines and applicable regulatory requirements.  
2.1 Background Information 
Open -angle glaucoma (OAG) is a chronic ocular disorder characterized by elevated intraocular 
pressure (IOP) with clinical signs of v isual field loss and/or optic nerve damage with patients rarely 
experience any ocular symptoms. If the condition is left untreated, irreversible vision loss due to 
optic nerve damage will occur. The effect of elevated IOP on the optic nerve is gradual , leading to 
vision loss that patients may not realizes until they have irreversibly lost a majority of their vision.  
Based on estimates from the World Health Organization and the Glaucoma Foundation, this chronic disease is believed to affect approximately 67 to 105 million people worldwide 
(Leonard  2002) and is the leading cause of irreversible blindness worldwide. In 2011, 2.71 million 
people in the United States had OAG, b y 2050 it is estimated that 6.3 million people in the United 
States will have OAG.  
Treatment however of OAG/ OH by nature is a disease where compliance tends to be a significant 
problem due to the fact patients lack positive feedback from treatment. Treatment benefits with 
topical hypot ensive medications  are designed to prevent worsening rather than improving visual 
function by reducing IOP , which is not noticeable by patients . 
Treatment compliance is therefore a key issue in the successful control of OAG/OH and the 
prevention of vision loss. Traditionally, the term compliance has been employed to mean the extent 
to which a patient  remembers  and complies with the physician 's advice of when , and amount of 
medication to use. When treating a condition with an ocular drop from a bottle , treatment also 
depends upon the patient s’ physical ability to properly instill/place the correct amount of the 
medication /drop on the eye . A patients’ ability to correctly self-administer  ocular drops can be 
affected by a number of factors such as coordination, manual dexterity, n, good vision, all of which 
tend to decrease in aging glaucoma patients , and the presence of co -morbid conditions (Choy et 
al. 2019). Study has also shown tha t adding a second medication is associated with a statistically 
significant decrease in compliance ( Robin 2005). 
Effective treatment of OAG/ OH is compounded if the drop is not appropriately placed on the eye. 
The ideal location for instilling/placing  of an eye drop is in the eyelid cul -de-sac, or directly onto 
the surface of the eye. Due to patient s having difficulty holding the eyelid open or unable to control 
reflex blinking during installation, results in ma ny missed glaucoma eye drops over time and can 
lead to suboptimal treatment or costly wasting of medication. In addition, m any OAG/OH patients, 
find it difficult applying the correct amount of pressure to the bottle to release only one drop at a 
time.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  19 Mati Therapeutics Inc. - CONFIDENTIAL  
 2.3 Potential Risks and Benefits  
2.3.1 Known Potential Risks 
Potential risks associated with the use of a Travoprost Evolute is not fully known. The risk 
associated with using a study plug  to deliver a sustain ed release of travoprost are anticipated to be 
similar than  those observed for travoprost ophthalmic solutions ( TRAVATAN®, TRAVATAN  Z® 
or IZBA ®) or the use of silicone punctal plugs. However, the combination of travoprost with a 
punctal plug may have unforeseen risks.  
In a 3 -month clinical trial involving 422 patients exposed to QD dosing of travoprost ophthalmic 
solution, 0.004% and 442 patients exposed to QD dosing of travoprost ophthalmic s olution 
0.003%, the most common ocular adverse reaction noted during the trial was ocular hyperemia. 
Other reported ocular adverse events reported at lower incident rates are listed in Table 1 . 
TABLE 1  
Ocular Adverse Events Observed in Controlled Clinical Trial with Travoprost  
Ophthalmic Solutions 0.004% and 0.003%  (TRAVATAN ®, TRAVATAN Z® or IZBA ®) 
30-50% of Subjects   5 to 10% of Subjects   1 to 4% of Subjects  
 Ocular Hyperemia  
 *Ocular hyperemia in  
 IZBA controlled  
 studies noted at 12%    Decreased VA  
 Eye Discomfort  
 Foreign Body  Sensation  
 Pain 
 Pruritus    Abnormal Vision  
 Blepharitis  
 Blurred Vision  
 Cataract  
Cells  
 Conjunctivitis  
  
 Dry Eye  
 Iris Discoloration  
 Keratitis  
 Lid Margin Crusting  
 Ocular Inflammation  
 Photophobia  
 Subconjunctival Hemorrhage  
 Tearing  
 
TRAVATAN® may gradually change eye color, increasing the amount of brown pigmentation in 
the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long -
term effects on the melanocytes and the consequences of potential injury t o the melanocytes and/or 
deposition of pigment granules to other areas of the eye are currently unknown. The change in iris color occurs slowly and may not be noticeable for months to years. Patients should be informed of 
the possibility of iris color chan ge. TRAVATAN, TRAVATAN Z® or IZBA ® product labels are 
provided in Appendices I, J &  K.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  20 Mati Therapeutics Inc. - CONFIDENTIAL  
 Primary risk factors for silicone  punctal plugs  for use in humans are ocular discomfort, epiphora, 
loss of plug, ocular inflammation, and subconjunctival hemorrhage. Less common, but serious, 
side effects are pyogenic granuloma, damage to the muscle at the opening of the punctum, 
canaliculitis, or migration of the plug into the canalicula requ iring irrigation or surgery. In previous 
studies using models of the proprietary plugs, adverse reaction s (AEs) were noted in subjects, 
including device migration, lacrimation increased, ocular discomfort, eye irritation, conjunctival 
hyperemia, inflammation of lacrimal passage, eye pain, and eyelid ede ma. 
2.3.2 Known Potential Benefits 
The potential benefit of the Travoprost Evolute® is the ability to deliver a sustain release of 
travoprost over a 90-day period, reducing a patient’s elevated IOP while eliminating his/her need 
to remember to correctly self -administer an eye drop on a daily basis  at a specific time of day . 
Additional benefits would include, relieving the difficult y some patients have instilling an ocular 
drop, or the uncertainty  they may have  if they properly instilled his/her drops. Uncertainty of drop 
instillation c an lead to either under dosing (drop instilled improperly) or overdosing , patient 
instilled first drop properly however, believes drop was not dosed properl y and instills a second  
drop. 
A summary of known benefits to humans of 0.004% or 0.003% travoprost ophthalmic drops can 
be found in the TRAVATAN®, TRAVATAN Z® or IZBA ® prescribing information (see Appendices  
I, J & K). 
3 OBJECTIVES AND PURPO SE 
Past clinical studies with topical dosing of 0.004% and 0.003% ophthalmic solutions of travoprost 
(TRAVATAN/TRAVATAN Z  and IZBA ) have demonstrated the safety and efficacy of travo prost 
ocular drops in the reduction of elevated intraocular pressure in patients with open- angle glaucoma 
or ocular hypertension. The objective for this study is to evaluate the use of a punctal plug delivery 
system  that can deliver a sustained, safe and effective concentration of travoprost to a subject with 
OAG/OH that can reduce elevated intraocular pressure. 
4 STUDY DESIGN AND ENDPOINTS  
4.1 Description of the Study Design  
This is a pilot, open- label, multi- center clinical study.  Each potential subject that has given HIPAA 
and informed consent and has meet all screening inclusion/exclusion criteria will discontinue the 
use of his/her topical hypotensive medication(s) for the next six-weeks.  In addition, during this 
perio d a potential study subject will also discontinue the use of all prohibited systemic medications, 
and all other ocular drops, gels or ointments that have not been prescribed by the investigator  24-
hours prior to Visit 2. 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  21 Mati Therapeutics Inc. - CONFIDENTIAL  
 4.2 Study Endpoints  
The study will be c omplete when up to 30 stud y subjects ( ~30 qualified eyes) have been evaluated 
at Visit 7 (Day 90 ± 7 days  post plug insertion) or have been terminated from the study. 
4.2.1 Primary  Endpoint 
The primary variable will be IOP changes from baseline  to Day s seven,  28, 60 and 90. P rimary 
analysis time point will be IOP s obtain between 8:00 and 10:00 am . Observed IOP and percent 
change from baseline in IOP will also be analyzed.  
4.2.2 Other Data Endpoints 
Secondary variables will look at changes in IOP and percent change between the screening and the 
baseline visits ( after washout phase, prior to insertion of any Travoprost Evolute®), percent of 
screened patient s that qualified for washout phase, percent of patients that entered the washout 
phase that qualified for the treatment phase, enrollment rates  (rates in to each phase of the study) , 
number and percent of study subjects whose IOPs were >34 mmHg at Visit 2, number and percent  
of eyes that extruded a Travoprost Evolute, number of eyes investigators were unable to di late or 
insert a study plug , listing of reasons why patients failed to qualif y. 
4.2.3 Safety Endpoints  
Safety variables include any reported AEs/SAEs. Safety variables will also include clinically 
significant changes in  IOP, BC DVA, slit -lamp findings, ocular tearing and comfort, blood 
pressure, heart rate, temperature, and Travoprost Evolute® inspections/extrusions. Safety analyses 
will be performed on all subjects who enter the washout phase of the study. Subjects that were 
inserted with a study plug w ill be subgrouped and summarized separately . 
5 STUDY ENROLLMENT AND WITHDRAWAL  
5.1 Study Population  
Up to 30 qualified male or female subjects ( ~30 qualified eyes) who have given HIPAA and 
informed consent, have met all screening and washout criteria, will be enrolled into the treatment 
phase of the study  and have a Travoprost Evolute inserted into the lower punctum of each eye. All 
study plugs will remain in the study subject’s lower puncta for a period of 90 + 7 days after 
insertion. 
5.2 Study Inclusion/Exclusion Criteria  
5.2.1 Study Screening Phase Criteria  
The following are criteria  a potential study subject must meet in order to be considered for 
enrollment into the study screening phase of the study. 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  22 Mati Therapeutics Inc. - CONFIDENTIAL  
 5.2.1.1 Screening  Phase - Inclusion Criteria 
The following are requirements a subject must meet in order to be considered for inclusion into 
the study screening phases of the study: 
1. Male or female subject, 18 years of age or older at the time of the screening examination and has been diagnosed with bilateral OAG or OH 
2. A subject must be able and willing to read, comprehend and give Authorization for 
Use/Disclosure of Health Information (HIPAA) and informed consent 
3. A subject must not have taken any ocular hypertension medication(s) within 12 hours of the 
screening visit  
4. A subject m ust be willing to have the lower puncta of each eye inserted with a study plug 
5. A subject’s screening visit (pre -washout) IOPs , measured between 8:00 and 10:00 AM, is less 
than 22 mmHg in both eyes 
6. A subject IOPs are currently controlled ( < 22 mm Hg) with a  topical prostaglandin or in 
conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.), in both eyes for at least one month 
7. A subject must be willing to comply with study instructions and agree to complete the entire 
course of the study 
 
8. A subject must agree to make all office appointments and have all office visits occur between 8:00 and 10:00 AM 
9. Women of child- bearing potential must not be pregnant or lactating, mus t have a negative 
pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal (“patch”), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide  
10. A subject has a Best-Corrected Distance (Glasses) , pinhole visual acuity of 20/100 (Snellen) 
or better in both eyes 
11. A subject  has documented perimetry results within the last 6 months prior to the Screening 
Visit for both eyes 
NOTE:  If perimetry measurement are older than 6 months, perform automated perimetry 
at the screening visit 
12. A subject  has documented central corneal thickness measurements between >500 µm and 
<600 µm in both eyes 
NOTE:  if corneal thickness data is not available, measure corneal thickness of each eye 
using pachymetry at the screening visit  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  23 Mati Therapeutics Inc. - CONFIDENTIAL  
 5.2.1.2 Screening Phase - EXCLUSION Criteria  
If any of the below criteria apply to a potential study subject, the subject does not qualify for 
enrollment into the screening phase of the study:  
1. A subject  with a history of non-response to topical prostaglandin eye drops for OAG/OH 
2. A subject with angle -closure glaucoma, neovascular glaucoma, traumatic glaucoma or 
iridocorneal endothelium syndrome in either eye 
3. A subject with a known sensitivity to travoprost, fluorescein, topical anesthetic, silicone, any 
inactive ingredient of the Travoprost Evolute® or any other products required for study 
procedures 
4. A subject with > 0.9 vertical cup or completely notched optic nerve head rim in either eye 
5. A subject with a ny functionally significant visual field loss or progressive field loss within 
the last year in either eye  
6. A subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye  
7. A subject with a history of intolerance to punctal plugs or a known sensitivity to any inactive ingredient of the punctal plug, silicone, topical anesthetic, or any other products required for the study 
8. A subject with structural lid abnormalities (i.e., ectropion, entropion) in either eye 
9. A subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, meibomianitis) that requires medical treatment  
10. A subject with any clinically significant (moderate or severe) lid, conjunctival or corneal 
findings in either study eye at the screening visit  
11. A subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye  
12. A subject who would require the use of any ocular medication(s), an over -the-counter 
drop(s), ointment(s) or gel(s), other than the study hypotensive medication(s) in either eye during the study period 
13. A subject who has had any ophthalmic s urgical procedures (i.e., glaucoma laser, minimally 
invasive glaucoma surgery, cataract, refractive, etc.) in either eye within the last six months or will require ophthalmic surgery before completing the study 
14. A subject with a history of penetrating kerat oplasty in either eye  
15. A subject requiring the use of a contact lens in either eye at any time during the study period 
16. A subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye 
17. A subject with  a history of macular edema in either eye  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  24 Mati Therapeutics Inc. - CONFIDENTIAL  
 18. A subject currently on any systemic medication [i.e., beta- blocker, carbonic anhydrase 
inhibitors, corticosteroids (including dermal), etc.] that may have an effect on the subject's 
IOP, or who will require its use  during the study period ( NOTE : an inhaled steroid, systemic 
beta-blocker or β- adrenoceptor antagonist may be permitted, providing the subject has 
maintained a stable dosage regimen for at least the last three months)  
19. A subject with an uncontrolled systemic disease or a medical condition that may increase the 
risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e.g., autoimmune disease if the subject is on chronic medications and has ocular involvement; host-versus- graft disease)  
20. A subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study. 
5.2.2 Washout Phase - C riteria  
After the screening phase (process), each subject meeting all screening inclusion/exclusion criteria must be willing to : 
1) DISCONTINUE  the use of his/her hypotensive medication for the next six -weeks (Note:  If 
desired, an investigator can perform the  six-week washout by placing the subject on mono-
therapy with a topical CAI for 5 weeks, then during the last week, discontinue the use of the topical CAI).  Each subject will be instructed not to use his/her hypotensive medication for the 
duration of the study 
2) DISCONTINUE  the use of  all other ocular drops, gels or ointments that have not been 
prescribed by the investigator, 24 hours prior to Visit 2 and for the duration of the study 
3) DISCONTINUE  all systemic medication that are PROHIBITED by the protocol for the 
duration of the study . Systemic medication(s) being used by a subject at the Screening visit 
and is permitted by the protocol, may continue the medication(s), however the concentration 
and dosing  frequency should remain the same throughout the washout and treatment phase of 
the study 
5.2.3 Study Treatment Phase Criteria  
5.2.3.1 Treatment Phase - INCLUSION Criteria : 
After the washout phase, the following are requirements a subject must meet in order to be considered for enrollment into the treatment phase of the study:  
1) After the six-week washout  phase, the subject continues to meet all screening phase 
inclusion/exclusion criteria  
2) After the six-week washout  phase, subject’s Baseline (Visit 2) IOP, measured between 8:00 
and 10:00 AM, is  ≥ 23.0 and < 34.0 mmHg in at least one eye  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  25 Mati Therapeutics Inc. - CONFIDENTIAL  
 3) Subject’s Baseline ( Visit 2, morning average)  IOP is > 5 mmHg from the subject ’s 
SCREENING (pre -washout) IOP in at least one  eye whose Baseline IOP is between > 23 and 
< 34 mmHg . 
4) Investigator is able to dilate the  lower puncta of each eye to 1.0 mm, and insert a study plug 
into each puncta. 
5.2.3.2 Treatment Phase - EXCLUSION Criteria  
If any of the below criteria apply to a study subject that has completed the washout period, the 
subject does not qualify for enrollment into the treatment phase of the study:  
1) A subject who no longer meets all the screening and washout study criteria  
2) A subject who cannot be successfully inserted  with a Travoprost Evolute® in the lower 
punct a of each  eye, even if only one eye qualifies for enrollment. 
5.3 Strategies for Recruitment and Retention  
To increase study subject enrollment and retention in the study, sites should dedicate an individual 
[Clinical Research Coordinator (CRC)] who is well inf ormed regarding the study design, required 
inclusion/exclusion criteria and visit schedule, as the main contact who is readily available to answer all potential subject questions and/or concerns about participating in the clinical study. The 
CRC should be prepared to discuss with a potential study subject the differences in the amount of time, examination procedures and visit schedule they would experience if they agreed to participate in the study.  In addition, should a subject agree to participate in the study, the CRC 
would be readily available as  his/her main contact person while participating in the study.  
To encourage recruitment and retention of a study subject, sites should offer a subject reimbursement for transportation cost (e.g. Uber, Lyft) and a  stipend for his/her time and effort for 
participation, offer less waiting time in the doctor’s office by scheduling more flexible and reliable appointment times.  In addition, discuss the advantages of participating in the study by not having 
to remember t o instilling his/her medication over the study period.  
5.4 Study Subject Withdrawal or Termination Criteria  
Each study subject will be informed that they are free to withdraw from the study at any time  
however, if they have been inserted with study plugs, the y must return to the investigator’s office 
to have the study plugs removed. The Investigator in consultation with the Medical Monitor, or 
the Medical Monitor may exercise his or her medical judgment to terminate a study subject’s participation in the study , if it is in the best interest of the study subject.  A terminated study subject 
will be followed through Day 90 or until the condition has resolved or has become medically 
stable.  
 
 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  26 Mati Therapeutics Inc. - CONFIDENTIAL  
 Medical Monitoring for this study will be conducted by: 
Robert Williams, MD 
Phone (Office):  360.378-7916 
Phone (Cell):  360.298-5325 
Email: iopdoc1@gmail.com 
The name of the Medical Monitor and contact information will be provided to each study site.  
Mati Therapeutics Inc. reserves the right to terminate the study at any time.  Every effort will be 
made to collect all data required by the protocol during or following the study subject’s early 
termination visit.  
5.4.1 Reasons for Termination, Discontinuation or Disqualified 
At a study subject ’s last visit (scheduled or unscheduled), a study subject  will have his/her  
study punctal plug s removed  and a study exit case report form (CRF) must be completed, 
whether or not the study subject completed the final study visit (Visit 7, day 90 ± 7 post-insertion). 
The reason for any early exiting from the study will be indicated on the study exit form and all efforts will be made to complete and report the observations as thoroughly as possible. The primary 
reason for a study subject early exiting the study should be selected from the following standard 
categories (see Sections  5.4.2 below). 
5.4.2 Reason s for Termination  
A study subject will be terminated from the study if in the Investigators medical judgment, it was in the best interest of the study subject that developed or reported: a) a lack of efficacy , b) reported 
a serious AE /ADE s, regardless of relation to the study drug/device or has died.  
5.4.2.1 Reason s for Discontinuation  
A study subject will be discontinued from the study : a) if the Investigator is unable to sufficiently 
dilate the punctum or insert a punctal plug in to the lower punct um of either  eye, b) if a subject has 
extruded a plug and a new plug cannot be re -inserted, c) if during the course of the study a subject 
has extruded a plug from each eye, d) if a subject has extruded a plug more than once f rom the 
same eye e) in a subject where only one eye qualified at Visit 2, if the plug is extruded in the 
qualified eye , f) if a subject has used a prohibited concomitant  ocular or systemic 
(OTC/prescription) medication/therapy, g) if a subject is  non-compliant and has missed scheduled 
study visits, h) for personal reasons, i) has relocated out of the area or has a desired to withdraw 
from further participation in the study in the absence of a medical need as determined by the Investigator. Other reason – the study subject was discontinued for a reason other than those listed 
above, the Investigator must specify the reason. 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  27 Mati Therapeutics Inc. - CONFIDENTIAL  
 5.4.2.2 Reason s for Disqualification  
A study subject will be disqualified from the study if there was a failure to obtain written informed 
consent or HIPAA Authorization, improper entry (did not meet all study inclusion/exclusion 
criteria), had a positive pregnancy test (at  Visit 1).  
5.4.3 Handling of Study Subject Termination, Discontinued or Disqualified 
5.4.3.1 Handling of Terminated Study Subject 
A terminated study subject will return to the clinic for an end of study safety evaluation and the removal of his/her punctal plugs. A terminated study subject will receive appropriate treatment at 
the discretion of the Investigator. Notification of termination will be clearly documented on the 
appropriate Case Report Form. A terminated study subject is considered to have completed the 
study and will NOT be rep laced . 
5.4.3.2 Handling of Discontinued Study Subject 
A study subject may voluntarily discontinue (withdraw) from the study at any time they choose. Notification of discontinuation will be clearly documented on the appropriate Case Report Form.  
If a study subject elects to withdraw from the study during the study treatment phase, the 
Investigator will make every effort to have the study subject return to the clinic for an end of study safety evaluation and the removal of the subject’s  punctal plug s. A study subject  who is 
discontinued from the study will be replaced . 
5.4.3.3 Handling of Disqualified Study Subject 
Notification of disqualification will be clearly documented on the appropriate Case Report Form. If a study subject was inserted with punctal plug s, the Investigat or will make every effort to have 
the study subject return to the clinic for an end of study safety evaluation and the removal of the punctal plugs. A study subject disqualified from the study will be replaced . 
5.5 Premature Termination or Suspension of Study or Study Site  
Mati Therapeutics Inc. reserves the right to terminate or suspended the study at any time.  Every 
effort will be made to collect all data required by the protocol during or following the study 
subject’s early termination visit.  
If representatives of Mati Therapeutics Inc., the Principal Investigator, the Study Monitor (Clinical Research Associate [CRA]), the Medical Monitor, or the FDA officials discover conditions arising during the study that indicate that the study should be halted or that participation by the study 
center should be terminated, this action may be taken after appropriate consultation with 
representatives of Mati Therapeutics Inc., the Principal Investigator, the CRA, and the Medical 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  28 Mati Therapeutics Inc. - CONFIDENTIAL  
 Monitor. Conditions that may warrant termination of the study include, but are not limited to the 
following: 
a. The discovery of an unexpected, serious, or unacceptable risk to a study subject enrolled in the 
study 
b. A decision on the part of Mati Therapeutics Inc. to suspend or discontinue testing, evaluation, or development of the product 
c. Failure of the Principal Investigator to enroll study subjects into the study at an acceptable rate  
d. Failure of the Principal Investigator to comply with pertinent FDA regulations and ICH Guidelines 
e. Submi ssion of knowingly false information from the research facility to Mati Therapeutics 
Inc., or designee, the CRA, the Medical Monitor, or the FDA 
f. Insufficient adherence to protocol requirements.   
Study termination and follow -up will be performed in compliance with the conditions set forth in 
21 CFR 312.50 and 21 CFR 312.56. 
6 STUDY AGENT  AND PROCEDURES  
6.1 Study Treatment  
Each investigational site will be assigned a site ID number (e.g., 100, 200 . . . 500). As a study 
subject qualifies for enroll ment  in to the screening phase of the study , they will be sequentially 
assigned a study ID number that corresponds with the site ID number (e.g., site ID = 100, subject 
sequentially assign numbers 101, 102, . . . 110).  If the potential subject does not qualify  after the 
washout phase, the subject ID number will be retired. A subject that has a Travoprost Evolute
® 
successfully inserted into the lower puncta of each eye , will be identified throughout the treatment 
period of the study by his/her assigned subject I D number  and initials . 
6.1.1 Route of Administration  
Each study subject that qualifies for the treatment phase of the study will have the lower puncta of 
each eye inserted with a Travoprost Evolute® (see Appendices  F and G for plug insertion details). 
Each study plug has a drug insert which contains a drug load of 166 µg of travoprost. 
If the investigator is unable to insert a study plug in both eyes, the subject will be discontinued 
from the study and his/her subject ID number will be retired . 
6.1.2 Formulation, Appearance, Packaging and Labeling 
6.1.2.1 Formulation  
The punct al plug component s of the Travoprost Evolute ( Figure 2) device consist of an inactive 
medical -grade silicone with a  2% green colorant  throughout the plug (colorant allows for ease of 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  29 Mati Therapeutics Inc. - CONFIDENTIAL  
 identif ication and evaluation  of plug placement) . The drug insert components of the study plug  is 
a thin -walled polyimide tube (core) filled with a solid sustained release matrix contain ing a drug 
load of 166 µg of travoprost (active ingredient). The drug insert is held in place via an interference 
fit between its outer and inner diameters of the punctal plug bore. 
Figure 2: Travoprost  Evolute System (L -shape  plug  Model L67)  
 
6.1.2.2 Appearance  
All Travoprost Evolute are L -shaped and will be provided preloaded  on a two- part insertion tool, 
as shown in Figure  3. 
Figure 3: Preloaded Insertion Tool with an L-Shaped Travoprost  Evolute  
 
 
6.1.2.3 Packaging  
A pre -loaded Travoprost Evolute® will be supplied preloaded onto the inserter tip in a preformed 
rigid tray.  Tray will be sealed with a foil laminate lid, heat sealed onto the tray and sterilized.   
6.1.2.4 Labeling  
Each tray containing a Travoprost Evolute will be labeled with an investigational drug statement 
in accordance with applicable regulations.  

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  30 Mati Therapeutics Inc. - CONFIDENTIAL  
 6.1.3 Product Storage and Stability 
All used and unused study plug products must be stored in a secure area with controlled access.  
All plugs must be stored at refrigerated  temperature (2° - 8°C).  All study punct al plug delivery 
system products have a retest  date indicated on their label . 
6.1.4 Starting Dose  
Upon insertion of a Travoprost Evolute, the drug insert contains a drug load of 166 µg with a drug 
elution rate of 1 to 2 µg  per day.   
6.1.5 Preparations and  Insertion of a Travoprost Evolute 
The Travoprost Evolute is for single -patient use only. The procedures for inserting a study plug 
are similar to those for commercial silicone plugs  and procedures for insertion of a study plug  are 
detailed in Appendices F & G. If the size of the study subject puncta ha s not be measured, gauge 
(Appendix E ) the size of each punctum prior to dilating. 
6.1.5.1 Determining Punctum Size (see  Appendix E  for detailed instructions ) 
Anesthetize the area around the lower punctum of each eye. Use a C oroneo P unctal Gauge  
(Figure 5) to determine the size of the punctum.  
NOTE:  Measurement of the punctum size should be evaluated prior to dilating the 
punctum.  
6.1.5.2 Dilation of the Lower Punctum ( Appendix F  for detailed  instructions) 
Prior to inserting a Travoprost Evolute , it is required that the lower punctum must be dilated to  
at least 1.0 mm . While dilating, prepare the study plug  to be inserted in the lower punctum of the 
study subject’s eye.  
a. If required, measurement of the punctum size should be evaluated prior to dilating the punctum. 
b. Procedure for dilating the punctum to at least 1.0 mm and inserting a study punctal plug should 
be performed on one eye at a time 
c. Anesthetize the area around the lower punctum, place a drop of topical anesthetic on the eye to be inserted. Then add lidocaine gel on a cotton-tipped swab and placing the swab direct ly 
on the lower punctum 
d. Use the Coroneo Punctal Gauge to dilate the punctum. The punctum must be dilated to at 
least 1.0 mm . Once the punctum is dilated to 1.0 mm, leave dilator in place for 15 to 30 
seconds to allow the sphincter to fully relax. 
NOTE : For  small puncta, hold and rotate the dilator in the punctum and canaliculus for as 
long as required to achieve dilation to 1.0 mm. This may take some considerable 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  31 Mati Therapeutics Inc. - CONFIDENTIAL  
 time. Dilation may require very firm pressure however; care must be taken NOT 
to apply excessive force to dilate the punctum . Add more anesthesia if needed.  
6.1.5.3 Procedure for Insertion of a Travoprost Evolute® (Appendix G  for detailed instructions ) 
Lubricants are NOT to be used to insert a Travoprost Evolute. Physicians inserting the study 
plug will have been briefed with the instructions and guidelines. It is recommended that the 
punctum be dilated to at least 1 mm prior to attempting insertion. After insertion, a slit- lamp will 
be used to verify the Travoprost Evolute is appropriately positioned.  
NOTE:  The punctum may constrict before the plug can be inserted, additional dilation 
would then be required. If a plug is partially inserted (e.g., cap not flush with the lid margin) the plug should be removed and the punctum re- dilated or dilated to a 
larger diameter.  
If the Travoprost Evolute cannot be inserted after a few attempts with gentle dilation, the subject 
is not eligible for the study.   
6.1.6 Instructions for Study Subjects after Travoprost Evolute Insertion 
A subject should be instructed not to attempt to remove or adjust the Travoprost Evolute on his/her 
own. In addition, instruct the subject to restrict eye rubbing, swimming, scuba diving, or other 
actions or activities that may result in physical manipula tion of the eye region. 
6.1.7 Procedure for the Removal of a Travoprost Evolute ( Appendix E for detailed instructions) 
The Travoprost Evolute should be removed from the study subject’s lower puncta using sterile 
ophthalmic forceps, such a s Castroviejo Suture forceps (Appendix H , Figure 6) or similar toothed 
forceps , with a gentle tugging motion.  A drop of anesthetic may be administered if necessary.  
NOTE:  Removal of a Travoprost Evolute immediately after insertion may result in 
the cap of the plug being torn off ; the Investigator should wait at least 24 hours 
after insertion before attempting to remove a study plug . Use of a jeweler’s forceps 
is not advisable 
a. Care must be taken not to grasp the outermost edge of the  cap on the punctal plug as this may 
cause the cap to tear and separate  
b. The motion to remove the plug should be towards the medial canthus (not up or temporally) 
If the cap becomes separated, try to remove the plug using toothed 0.12 forceps (0.12 Castrovi ejo 
forceps or similar) by grasping the neck of the plug through the punctum.  If this is not possible, 
and only if you feel comfortable doing so, you may attempt to irrigate the canal until the plug flushes out of the nasolacrimal duct.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  32 Mati Therapeutics Inc. - CONFIDENTIAL  
 NOTE : Study plugs are larger than commercially available silicone plugs and may become 
lodged in the canal more easily. Referral to tertiary care is advised in cases where 
the plug cannot be retrieved by massaging/milking through the punctal opening or by irriga tion.  
6.1.8 Unable to Insert/Extruded/Lost Travoprost Evolute
® 
If either eye of a study subject cannot be dilated to at least 1 mm, the subject will not be eligible 
for the study. 
6.1.8.1 Unable to Insert Travoprost Evolute 
If a Travoprost Evolute cannot be inserted af ter a few attempts with dilation, the subject will not 
be eligible for the study.  Lubricants are NOT  to be used .  
NOTE:  If the first attempt to insert a plug was successful however, the investigator is 
unable to insert the second plug, the first plug will be removed and the subject will 
be discontinued from the study. Removal of a Travoprost Evolute  immediately 
after insertion may result in the cap of the plug being torn off ; the Investigator 
should wait at least 24 hours after insertion of the study plug . Retain the plug for 
accountability of investigational supplies. 
6.1.8.2 Extrusion of a Travoprost Evolute 
A study subject that has noticed a study plug has been extruded or los t during the treatment phase, 
the study subject should immediately contact the Investigator and/or his/her staff and return to the 
Investigator’s office as soon as possible . If the study subject can find the extruded plug, they should 
return with the plug  where the Investigator and/or his/her staff will collect  and retained the plug 
for investigational supply accountability. If the return plug has torn or has separated, report this as 
a technical complaint ( Section 8.6). If a study plug has been lost, the Investigator will retro -
illuminate or palpate the canaliculi to confirm the plug has not migrated into the canal. Information regarding the loss of any plug must be recorded in the source documents, CRFs and Accountability Logs.  
If a single plug has been extruded during the study , the Investigator will re -insert a new plug and 
instruct the study subject to return to the investigator office based on their originally study visit(s)  
scheduled . At any time during the study, a study subject experiences a second extrusions or a n 
extrusion in the fellow eye , the study subject will return to the Investigator’s office as soon as 
possible and will have the remaining plug removed. The study subject will be discontinued from the study and WILL be replaced.  
6.1.9 Duration of Therapy 
Each subject will have a Travoprost Evolute
® inserted in to the lower punctum of each eye. The 
study plug will remain in the study subject’s lower puncta for a period of 90 ± 7 days.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  33 Mati Therapeutics Inc. - CONFIDENTIAL  
 6.2 Study Plug Accountability Procedures  
The Investigator is responsible for maintaining the study treatment (punctal plugs) accountability 
log, which will contain inventory records acknowledging the receipt and dispensing of all study plugs. The study center will keep a complete accounting of all used, unused, damaged, extruded and lost study plugs. All lost/extruded study  plugs must be recorded into the accountability log 
and on the CRFs of the study subject who lost/extruded a study plug, noting the suspected date the study plug was lost/extruded.  
All used and unused study plugs must be accounted for and kept in the desi gnated secure area at 
the study center until the Sponsor provides instructions for the return of all study materials. Final 
accountability for investigational study plugs will be verified by the Sponsor and/or their representatives and considered complete when the study plugs are no longer actively used and all 
study plugs (used, unused, extruded, lost) have been accounted for and returned to the Sponsor.  
7 STUDY PROCEDURES AND SCHEDULE  
Data will be captured and compiled using procedures developed by representatives of Mati Therapeutics Inc. All requested study data must be recorded clearly on study NCR CRFs and other study forms, as required. An explanation must be provided for all missing data. Only the Investigator or his/her staff members who are identified on the Study Personnel Delegation of Authority form may enter or correct data on a CRF. Incomplete or inconsistent data on the CRFs will result in data queries that will require resolution by the Investigator.  
7.1 Protocol Amendments  
Modification of the protocol is prohibited without prior written agreement in the form of a protocol amendment. All amendments will be created by the Sponsor and must be approved by the IRB prior to implementation except when required to mitigate immediate safety risks or when th e 
changes involve only logistical or administrative revisions. 
7.2 Study Procedures/Evaluations  
7.2.1 Study Specific Procedures 
Procedures that are required during the course of the study include ( Appendix C  for details) : 
a. Informed consent and HIPAA authorization:  The Investigator and or qualified staff will 
review and answer any questions a potential study subject may have regarding the study, the 
consent or HIPAA authorization forms. Prior to the initiation of any study specific activities, the subject must sign both documents 
b. WOMEN OF CHILDBEARING POTENTIAL, urine pregnancy tests are required at the screening visit and when the female subject exits the study  
c. Record subject’s demographic data and medical history for the previous 6 months  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  34 Mati Therapeutics Inc. - CONFIDENTIAL  
 d. Concomitant Medication use: All prescription systemic, ophthalmic and over -the-counter 
concomitant medications that will be used by the study subject will be documented.  The 
medication name, start and stop dates, indication, dose, route of administration and any dosing 
alterations during the study period must be documented on the Concomitant Medications CRF  
e. Verify a subject has followed all instructions regarding the discontinuation of any hypotensive ocular medication during the course of the study 
f. Vital Sign s (Temperature, Blood Pressure and Heart Rate): Throughout the study vital signs 
will be taken with the subject in the sitting position after the subject has rested five minutes. Techniques used to collect vital signs should remain consistent throughout the study  
- Temperature maybe taken using a non -contact (Infrared) thermometer or orally. Oral 
temperatures should not be taken within five minutes of ingestion of any food or drink 
- Blood pressure may be determined manually with a blood pressure cuff and auscultation 
or with an automated Blood Pressure monitor 
- Heart rates may be determined electronically with an automated Blood Pressure monitor. 
Manually obtained heart rates should be recorded after a minimum of 30 seconds of 
observation. 
g. Best-Corrected Distance Visual Acuity testing: Visual acuity with correction ( e.g., wearing 
glasses) will be measured using a Snellen chart. Pinhole visual acuity will be measured using 
a Snellen chart while the subject is looking through a pinhole occluder. The test dis tance and 
lighting conditions specified for the Investigator’s chart must be used and kept constant throughout the study  
h. Automated Perimetry  (visual fields) will be measured using a Humphrey's Visual Field 
Analyzer (manufactured by Carl Zeiss Meditec Inc. , Dublin, CA) with at least a standard full -
threshold 24- 2 program or Swedish interactive threshold algorithm (SITA) program. Visual 
fields measured  and documented up to SIX months before the Screening Visit are 
acceptable to fulfill the screening criteria  
i. Pachymetry can be measured by contact methods, such as ultrasound and confocal microscopy (CONFOSCAN), noncontact methods such as optical biometry with a single Scheimpflug camera (such as SIRIUS or PENTACAM), dual Scheimpflug camera (such as GALILEI), or  Optical Coherence Tomography (OCT), such as Visante. Past corneal 
thickness measurement documented in the subject’s chart  are acceptable to fulfill the 
screening criteria  
j. Slit-Lamp Examination: Examination will include assessment of the lid, conjunctiva a nd 
cornea. Grading of slit-lamp findings are defined in Appendix C . 
k. Perform a NON -DILATED  fundus exam of each eye. Using an ophthalmoscope, the 
investigator will examine the back part of the eye (fundus), including the retina, optic disc, choroid and blood vessels and evaluation of the lens 
l. Goldmann applanation tonometry will be used for measuring IOP. IOPs will be measured in the morning between 8:00 and 10:00 am. The IOP of each eye will be measured twice, alternating between the eyes. However, if the second measurement is ≥ ± 3 mmHg from the 
first measurement for an eye, a third measurement will be taken. All measurements taken will 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  35 Mati Therapeutics Inc. - CONFIDENTIAL  
 be recorded. In the case of two measurements, the average of the two values will be used for 
analysis, and in the case of three measurements, the average of the two closest values of the three will be used for analysis for that eye at that specific time point.  
NOTE : Just prior to the start of the study, the tonometer should be calibrated. 
m. Punctal size evaluation and dilation of the punctum (see Appendices E  & F for details),  
n. Insertion and removal of study punctal plugs (see Appendix G  & H for details )  
o. Adverse Event/Adverse Device Event  reporting, Section 8.7 of the protocol for details: To 
optimize consistency of AE/ADE reporting across centers, the study subject will be asked a 
standard question to elicit any AE/ADEs. At each study visit or telephone evaluation of the 
study subject, study personnel will ask the following question: 
“Have you had any problems since you r last visit? ” 
7.2.2 Standard of Care Procedures  
At any study visit (scheduled or unscheduled), in addition to study specific examinations the 
Investigator will perform their  standard evaluations for an OAG or OH patient.  
7.3 Laboratory Procedures/Evaluations  
Not applicable  
7.4 Study Visit Phases/ Schedule  
7.4.1 Visit 1 - Screening Phase (Qualification Visit)  
At this visit, prior to any study specific procedure or examination, a subject must read, comprehend 
and give  written  Authorization for Use/Disclosure of Health Information (HIPAA) and Informed 
Consent to participate in the study.  Once all forms have been signed , the investigator and/or his or 
her staff will perform the following screening assessments/examinations .  
a. Verify a subject has not used any hypotensive ocular drops within the last 12 hours of the 
screening visit  
b. A female subject of child- bearing potential will have a urine pregnancy test  performed  
c. Record subject’s demographic data and medical history for past 6 months 
d. Measure subject’s temperature, heart rate and blood pressure  
e. Record subject’s Best-Corrected (Glasses) Distance or Pinhole Visual Acuity  
f. Verify automated perimetry results have been measured and documented in the subject’s chart 
within the last 6 months 
NOTE : If perimetry measurement are older than 6 months, perform automated perimetry 
at the screening visit 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  36 Mati Therapeutics Inc. - CONFIDENTIAL  
 g. Verify corneal thickness measurements are documented in the subject’s chart  
NOTE : If corneal thickness data is not available, measure corneal  thickness of each eye 
using contact or non- contact pachymetry at the screening visit  
h. Perform a slit -lamp examination of each eye  
i. Perform a non -dilated fundus exam of each eye, including the evaluation of the lens 
j. Record IOP measurement of each eye  
k. Record concomitant medication use  
If at any time during the screening examination it is determined a subject does not meet a screening 
inclusion/exclusion criterion, at that point any additional screening assessments -examinations will 
be discontinued.  
After t he screening procedures and examinat ions have been completed, each qualified subject that 
meets all study inclusion/exclusion criteria will be asked to enter the washout phase of the study  
and will be sequentially assigned an ID number  (Section 6.1). In addition, the ID number and the 
study subject initials will be recorded on study case report forms, in lieu of recording his/her name, 
in order to maintain subject confidentiality.   
7.4.2 Washout Phase ( Six-week duration) 
During the washout phase of the study, each subject will be instructed to discontinue the use of 
his/her topical hypotensive medication(s) for the next six-weeks.  In addition, the subject will be 
instructed not to use any other ocular drops, gels or ointme nts 24 hours prior to the Baseline visit 
(Visit 2)  in his/her eyes that have not been prescribed by the investigator. 
Systemic or topical medications that are being used at the Screening Visit, that are considered 
necessary for the subject’s welfare and ar e PERMITTED  by the protocol ( Sections 5.2.1), may 
continue to be used as long as the concentration and dosing frequency of the medication(s) will 
remain the same through out the entire duration of the study.  
Systemic medication s that are PROHIBITED  by the protocol, must be discontinued during the 
washout phase. All ocular drops, gels or ointments being used by the subject must be discontinued 
24 hours prior to Visit 2. Should the subject qualify for the treatment phase of the stud y, they will 
be asked to continue for an additional  90 ± 7 day s not to use any systemic or topical medications 
during the treatment phase of the study. 
7.4.3 Treatment Phase (Visits 2, 3 , 4, 5, 6 & 7) 
At the completion of the washout phase ( 6-weeks)  each subject  that continues to meet all study 
screening , washout  and baseline criteria will have the lower puncta of each eye inserted with a 
Travoprost Evolute® and scheduled to return to the investigator’s office for follow -up 
examinations at one , seven , 28, 60 and 90 days after insertion of the study plugs.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  37 Mati Therapeutics Inc. - CONFIDENTIAL  
 7.4.3.1 Visit 2 - Day 0, Plug Insertion Visit (Baseline) 
Qualified subject will undergo the following: 
a. Verify a subject has  not used any hypotensive ocular drops during the washout phase 
b. Verify whether there are any changes in the medical history and confirm the subject still meets 
all study inclusion/exclusion criteria  
c. Record any addition, discontinuation or changes in the subject's use of any concomitant 
medications or ocular drops, gels or ointments during study washout phase 
d. Record subject’s temperature, heart rate and blood pressure 
e. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
f. Perform a slit -lamp examination of each eye  
g. Record IOP measurement for each eye  
h. Record any Adverse Events/Adverse Device Event . 
After the baseline procedures and examinations have been completed, a subject that meets the 
baseline IOP inclusion criteria (Section 5.2.3)  will have their punctal size of each eye evaluated  
and will be inserted with a Travoprost Evolute into the lower puncta of each eye  even if only one 
eye qualifies . 
i. Dilate the lower puncta to 1.0 mm and insert a study plug  into the lower punctum of each eye 
(refer to Sections 6.1.5.2 & 6.1.5.3 for details regarding punctum dilation and punctal plug 
insertion techniques) 
j. Evaluate after insertion, the position of the study plugs in each eye using the slit- lamp  
NOTE:  At the conclusion of the visit a subject does not meet all treatment 
inclusion/exclusion criteria or  the investigator is unable to insert a Travoprost 
Evolute into the lower puncta of each eye, the study subject will be discontinued 
from the study. The subject ID number will be retired. If the investigato r was 
able to insert only one study plug , the one inserted study plug  must be removed 
(Section 5.4) 
Each study subject will be instructed not to attempt to remove or adjust the punctal plug on his/her 
own. In addition, encourage each study subject to restrict eye rubbing, swimming, scuba diving, 
or other actions or activities that may result in physical manipulation of the eye region  
Each study subject will be scheduled to return the next day for a follow -up study examination 
(Visit 3, day 1 post-plug insertion).   
NOTE:  At any time during the treatment phase, a  study subject has noticed a plug has been 
extruded or lost they should imm ediately contact the Investigator and/or his/her 
staff and return to the Investigator’s office as soon as possible ( Section 6.1.8.2).   
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  38 Mati Therapeutics Inc. - CONFIDENTIAL  
 7.4.3.2 Visit 3 - Day 1, Post-P lug Insertion 
a. Verify a subject has  not used any hypotensive ocular drops since his/her last visit  
b. Record any addition, discontinuation or changes in the subject's use of any concomitant 
medications or ocular drops, gels or ointments since his/her last visit 
c. Record subject’s temperature, heart rate and blood pressure 
d. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
e. Evaluate the position of each Travoprost Evolute® using the slit- lamp  
f. Perform a slit -lamp examination of each eye  
g. Record IOP measurement for each eye  
h. Record any Adverse Events/Adverse Device Event  
NOTE:  Should a study subject exit the study early (after Visit 2 and before Visit 7), the 
subject must undergo all test and procedures scheduled for Visit 7 (Final Visit) . 
7.4.3.3 Visit 4 - Day 7  ± 1, Post- Plug Insertion  
a. Verify a subject has not used any hypotensive ocular drops since his/her last visit 
b. Record any addition, discontinuation or changes in the subject's use of any concomitant medications or ocular drops, gels or ointments since his/her last visit 
c. Record subject’s temperature, heart rate and blood pressure 
d. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
e. Evaluate the position of each Travoprost Evolute® using the slit- lamp  
f. Perform a slit -lamp examination of each eye  
g. Record IOP measurement for each eye  
h. Record any A dverse Events /Adverse Device Event  
NOTE:  Should a study subject exit the study early (after Visit 2 and before Visit 7), the 
subject must undergo all test and procedures scheduled for Visit 7 (Final Visit).  
7.4.3.4 Visit 5 - Day 28 ± 3, Post- Plug Insertion  
i. Verify a subject has not used any hypotensive ocular drops since his/her last visit 
j. Record any addition, discontinuation or changes in the subject's use of any concomitant medications or ocular drops, gels or ointments since his/her last visit 
k. Record subject’s temperature, heart rate and blood pressure 
l. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
m. Evaluate the position of each Travoprost Evolute® using the slit- lamp  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  39 Mati Therapeutics Inc. - CONFIDENTIAL  
 n. Perform a slit -lamp examination of each eye  
o. Record IOP measurement for each eye  
p. Record any Adverse Events/Adverse Device Event  
NOTE:  Should a study subject exit the study early (after Visit 2 and before Visit 7), the 
subject must undergo all test and procedures scheduled for Visit 7 (Final Visit).  
7.4.3.5 Visit 6 - Day 60 ± 5, Post- Plug Insertion  
q. Verify a subject has not used any hypotensive ocular drops since his/her last visit 
r. Record any addition, discontinuation or changes in the subject's use of any concomitant 
medications or ocular drops, gels or ointments since his/her last vi sit 
s. Record subject’s temperature, heart rate and blood pressure 
t. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
u. Evaluate the position of each Travoprost Evolute® using the slit- lamp  
v. Perform a slit -lamp examination of each eye  
w. Record IOP measurement for each eye  
x. Record any Adverse Events/Adverse Device Event  
NOTE:  Should a study subject exit the study early (after Visit 2 and before Visit 7), the 
subject must undergo all test and procedures scheduled for Visit 7 (Final Visit).  
7.4.3.6 Visit 7 - Day 90 + 7, Post- Plug Insertion (Final Study Visit)  
At this visit the following will be performed and recorded: 
a. Verify a subject has  not used any hypotensive ocular drops since his/her last visit  
b. Record any addition, discontinuation or changes in the subject's use of any concomitant medications or ocular drops, gels or ointments since his/her last visit 
c. If performed at SCREENING Visit, perform a urine pregnancy test on a female subject of 
child -bearing potential  
d. Record subject’s temperature, heart rate and blood pressure 
e. Record subject’s Best -Corrected (Glasses) Distance or Pinhole Visual Acuity  
f. Evaluate the position of each Travoprost Evolute using the slit- lamp prior to removal  of the 
plug 
g. Perform  a slit-lamp examination of each eye prior to study plug removal  
h. Record IOP measurement for each eye before study plug  removal  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  40 Mati Therapeutics Inc. - CONFIDENTIAL  
 i. Removal of the study plug  from each eye (refer to Section 6.1.7 f or details regarding removal 
of a punctal plug) 
j. Record any reported Adverse Events/Adverse Device Event  
An exit form will be completed at the final study examination (Visit 7), or whenever the study 
subject completes or leaves the study for any reason.   
NOTE:  The day each Travoprost Evolute® are removed with no addition follow -up 
required, will be the study subject’s official exit date from the study.  However , if 
the subject is exiting from the study due to an AE/SAE  or ADE/SADE , the 
study subject will be followed and exam findings r ecorded by the investigator 
until the AE/SAE  or ADE/SADE  has resolved or has become medically stable.   
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  41 Mati Therapeutics Inc. - CONFIDENTIAL  
 Schedule of Assessments, Events  
Visit Examination Parameters   Visit 1 
Screening   Visit 2  
(Day 0)   Visit 3  
(Day1)   Visit 4  
(Day 7)   Visit 5 
(Day28)   Visit 6   
(Day 60)   Visit 7   
(Day 90)  
Inform ed Consent/HIPAA                    
Medical Hx (past 6 months)/Demographic Data             A           
Urine Pregnancy Test  (Only women of childbearing potential )      B                B 
Concomitant Med Use                                            
BT ( temperature ), BP ( blood pressure ), HR ( heart rate )                                           
Evaluate study plug position prior to any eye exam         *                               
Best-Corrected Distance (Glasses) or Pinhole VA                                            
Automated Perimetry  (Not required  if measured in last 6 months )                   
Pachymetry  (Not required  if documented in patient’s chart )                   
Slit-Lamp Examination                                            
IOP ( Goldmann ) Evaluation  (To be measured between 8 and 10 am )                                           
Non-Dilated Fundus Examination  (Include evaluation of the LENS )                   
Begin Six -Week Washout  (D/C all topical drops, gels, ointments )                   
Punctal Size Evaluation, Dilation of Lower Puncta                    
Insertion of Punctal Plugs                    
**Punctal Plug Extrusion          C     C,D     C,D     C,D       
Removal of Punctal Plugs after eye exam completed                    
Adverse Event/Adverse Device Event Recording                                        
               
Keys to Abbreviations : 
A = Verify no change in medical history, subject still meets all study inclusion/exclusion criteria  
B = If performed at the screening visit, must be performed when subject exit the study  
C = In a subject where both eyes qualified at Visit 2, i f a plug is extruded in one eye, plug is to be replaced  and subject continues in the study  
D = In a subject where only one eye qualified at Visit 2, i f the plug is extruded in the qualified  eye, the subject will be DISCONTINUED and replaced.  In a subject where both eyes qualified, i f a 
plug is extruded in one eye, then extruded again or in the fellow eye, the subject will be DISCONTINUED and replaced  
* = Plug position evaluated after eye exam and plug insertion  
 = If subject EXITs the study after visit 2, but before visit 7, subject  must return to Investigator’s office to have plugs removed  
 
Body Temperature:  Temperature maybe taken using a non -contact (Infrared) thermometer or orally. Oral temperatures should not be taken within five minutes of ingestion of any food or drink  
Heart  Rate:  Heart rate taken in the sitting position after subject has rested for 5 minutes.  Recorded values can be obtained electronically (automated) or manually (observed for 30 seconds or more)  
Blood  Pressure:  Blood pressure, taken in the sitting position after subject has rested for 5 minutes.  Recorded values can be obtained electronically (automated) or manually  
Plug Position Evaluation:  Position of the plug will be evaluated as either:  Normal , Present but requires adjustment,  Extruded/Recovered , Extrud ed/Lost , Other  
Slit-Lamp Exam:  Evaluation will include the Lids (Upper & Lower), Conjunctiva (Bulbar & Palpebral) and the Cornea.  SL Findings will be graded on a 5-point scale:    
     0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe  
IOP Evaluation:  Goldmann applanation tonometry will be used for measuring IOP.  Just prior to the start of the study, the tonometer should be calibrated.  IOP of each eye will be measured twice,  
     alternating between the eyes.  The average of the two measurements will be used for analysis.  However, if there is a > ± 3 mmHg difference between the 1st and 2nd measurement  
     for an eye, a 3rd measurement will be taken and the average of the two closest values of the three will be used for analysis for that eye.  
 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  42 Mati Therapeutics Inc. - CONFIDENTIAL  
 7.5 Unscheduled Visit  
The investigator has the option of bringing a study subject back in for an unscheduled visit any 
time during the  washout or treatment phase  of the study for safety reasons (e.g., subject complaint 
of moderate or severe ocular symptoms, an AE). An unscheduled visit CRF should be completed. 
At minimum the investigator should record the following: 
a. Record any change in concomitant medication use 
b. Inspection of both punctal plugs via the slit- lamp  
c. Slit-Lamp examination, both eyes 
d. Measure IOP, both eyes 
e. Recording of any reported adverse events /adverse device events  
7.6 Early Exit Visit  (Disqualified, Discontinued or Terminated Study Subject ) 
Any study su bject exiting the study early  must undergo all test and procedures scheduled for Visit 
7 (Day 90 ± 7 days, post-plug insertion) and all result s recorded on the appropriate CRFs.   
NOTE:  Refer to Section 7.4.3.6 for details on procedures and examination to take place 
on the final study subject visit  
An exit CRF (Case Report F orm) will be completed whenever the study subject completes or 
leaves the study for any reason. A study subject will be exited from the study on the day t he 
Travoprost Evolute® are removed from both eyes with no additional  follow- up required. However , 
if the subject is exiting from the study due to an AE/ADE, the study subject will be followed 
and exam findings recorded by the investigator until the AE /ADE  has resolved or has become 
medically stable .   
7.7 Emergency Anaphylactic or Overdose Procedures, Dose Modifications  
Dose modification of the study drug/device is not possible or required in this study.   
NOTE : Use caution when inserting a study plug  to a subject who has previously exhibited 
sensitivities to phenylacetic acid derivatives and salicylate hypersensitivity as the potential for cross -sensitivity exists.  This study is not expected to cause AEs 
different in type or intensity from those previously reported in published clinical research literature regarding the use of topical travoprost ophthalmic solutions 
0.004% & 0.003% (TRAVATAN ®, TRAVATAN Z®, IZBA ®). Refer to the 
Investigator Brochure and Appendices I, J &  K for additional information. 
Should a subject experience a significant medical issue, the subject may be treated according to the Investigator’s medical judgment.  Any changes, discontinuation or addition of a  topical or 
systemic medication(s) must be recorded on the Concomitant Medication CRF. 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  43 Mati Therapeutics Inc. - CONFIDENTIAL  
 7.8 Concomitant Medication  
During the washout and treatment phases of the study, each subject will be instructed not to use 
any other ocular drops, gels or ointments in his or her eyes  that have not been prescribed by the 
investigator. Systemic or topical medications that are being used at the Screening Visit, that are 
considered necessary for the subject’s welfare and are perm itted by the protocol ( Section  5.2.1.2  
for details), may continue to be used as long as the concentration and dosing frequency of the 
medication(s) remain s the same throughout the entire washout and treatment phases of the study.  
7.8.1 Pre-Study Concomitant Medication Use 
Pre-study concomitant medication  is defined as a prescription and/or an  over-the- counter (OTC) 
medication  taken within 2 months  (whether continuing or not) prior to Visit 1 (S creening Visit ). 
All prior medications must be documented on the Concomitant Medi cations CRF.  
7.8.2 Concomitant Medication Use during Study 
Each study subject will be instructed not to use any other ocular drops, gels or ointments in his /her 
eyes that have not been prescribed by the Investigator. Systemic medications being used at 
screening visit that are permitted by the study protocol (see inclusion/exclusion criteria for details), 
are considered necessary for the study subject’s welfare, and will not interfere with the study may be used.   
All prescription systemic, ophthalmic and over -the-counter concomitant medications used during 
the washout and treatment phase of the study, that are considered necessary for the study subject’s 
welfare, and will not interfere with the study, may be used but must be documented on the Concomitant Medicatio n CRF. The use of all concomitant medications during the study, except 
for routine medications given for ocular study procedures required by the protocol (i.e., topical 
anesthetic for plug insertion ), will be documented. The medication name, start and stop dates, 
indication, dose, route of administration and any dosing alterations must be documented on the Concomitant Medications CRF through completion of the last study visit.  
Systemic or topical medications that are being used at the Screening Visit, that are considered 
necessary for the subject’s welfare and are permitted by the protocol (Section 5.2.1.2, criteria 12 
& 18, for details), may continue to be used as long as the concentration and dosing frequency of the medication(s) will remain the same throughout the entire duration of the study.  
7.9 Prohibited Medications, Treatments and Procedures  
7.9.1 Prohibited Medications 
After the screening  visit, the use of any ocular drops, gels or ointments in either eye is prohibited, 
with the exception for routine topical medication given for an ocular study procedure(s) that is 
required by the protocol (i.e., topical anesthetic) . Systemic or topical me dications being used at 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  44 Mati Therapeutics Inc. - CONFIDENTIAL  
 the Baseline Visit that are per mitted by the protocol ( Section  5.2.1.2, criteria 12 & 18, for details), 
are considered necessary for the subject’s welfare, and will not interfere with the study may be 
used.   
7.9.2 Prohibited Treatments  
The following are prohibited during the study washout and treatment periods: 
a. Use of homeopathic remedies  (e.g., gin gko biloba, cayenne pepper, bilberry, etc.) 
b. Significant changes to eating or drinking habits (i.e., begin a diet, increase or decrease alcohol, 
caffeine or water intake, etc.)  
c. Significant changes in physical exercise/yoga  
d. Use of marijuana  
7.9.3 Prohibited Procedures 
The following procedures are prohibited during the study washout and treatment periods: 
a. Laser trabeculoplasty  
b. Trabeculectomy  
c. Tube shunt surgery 
d. Cataract surgery  
7.10 Rescue Medication (s) 
7.10.1 Administration of a Rescue Medications 
A subject with an elevated IOP (>34 mmHg) or undue medical risk in either eye should be 
prescribed his/her glaucoma regimen they were using prior to entering the study  The use of a 
rescue medication will be considered prohibited medication and will be considered a protocol deviation and the study subject will be terminated from the study.  Reason for termination on the 
exit form should be listed as  “due to lack of efficacy”.  
8 ASSESSMENT OF SAFEETY 
8.1 Safety Variables 
Safety variables for this study will include an y reported AE/ADE  and rescue medication use. 
Safety variables will also include clinically significant changes in IOP, BCDVA, slit -lamp 
findings, ocular tearing and comfort, blood pressure, heart rate, temperature, extrusion of a 
Travoprost Evolute
®, or technical issues with the study plug  (e.g., cap of study plug  tears or 
becomes separated during plug removal.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  45 Mati Therapeutics Inc. - CONFIDENTIAL  
 To optimize consistency of A E/SAE reporting across sites, the study subject will be asked a 
standard question to elicit any AE/SAE . At each study visit or telephone evaluation of the study 
subject, study personnel will ask the following question:   
"Have you had any problems since your last visit?" 
8.2 Definitions  
8.2.1 Adverse Event  
Adverse Event (AE):  any un anticipated sign (including a clinically significant abnormal laboratory 
finding), symptom, or disease temporally associated with the administration of a medicinal 
product, whether or not considered related to the investigational product or device.  
Medical conditions or diseases present before a subject starts study treatment are only considered 
AEs if they worsen after the subject starts study treatment.  
8.2.2 Serious Adverse Event 
Serious A dverse Event (SAE): defined as any AE that (at any dose):  
• Results in death  
• Is life -threatening.  NOTE:  The term "life -threatening" refers to an event in which the subject 
was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more intense  
• Requires inpatient hospitalization or prolongs existing hospitalization  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• May jeopardize the subject or may require intervention to prevent one of the outcomes listed 
above. Medical and scientific judgment should be exercised in deciding if these events should 
be considered serious. Examples of such events are intensive treatment in an emergency room 
or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse. 
In addition, an AE that results in overdose or produces congenital abnormality or cancer is always 
considered an SAE.  
A subject admitted to a hospital as a result of an AE, even if released on the same day, would 
qualify for inpatient hospitalization.  An emergency room visit that results in admission to the 
hospital would also qualify for inpatient hospital ization.  However, emergency room visits that do 
not result in admission to the hospital would not qualify for inpatient hospitalization and, instead, should be evaluated for one of the other criteria for SAEs (e.g., life -threatening AE or medically 
significant event).  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  46 Mati Therapeutics Inc. - CONFIDENTIAL  
 Hospitalization scheduled before a subject enrolls in the study is not the result of a 
treatment -emergent AE, and therefore events leading to such hospitalization will not be considered 
study AEs or SAEs.  During the study, if a subject has elective surgery for a condition present at 
screening  into the study, and the condition did not worsen during the study, the reason for elective 
surgery, and resulting hospitalization (if applicable), should not be considered or reported as an 
SAE.  Surgery or hospitalization should always be reported as an outcome of an AE. For AEs that 
result in persistent or significant disability/incapacity, refers to a substantial disruption of a subject's ability to carry out normal life functions.  
The investigator must also submit documentation of the following to the Institutional Review Board, Ethics Committee, or Research Ethics Board (collectively referred to as an IRB):  
• Site-specific SAEs and follow -up: The type of serious event that must be submitted (e.g., all 
or only suspected), as well as the required timing of submission (e.g., within 10 days of 
occurrence), is defined by the IRB and regulations/guidance from regulatory authorities.  
• Any documentation provided by the Sponsor regarding reportable SAEs from the study:  The 
Sponsor will provide documentation of reportable events to the investigator, as specified in 
Section 8.7. 
The investigator should ensure that the subject receives appropriate medical treatment and that the subject is fo llowed up until the SAE resolves or becomes chronic, as defined in Section 8.4. 
8.3 Adverse Event Descriptions  
8.3.1 Intensity 
The intensity of AEs will be characterized as mild, moderate, or severe, as follows: 
• Mild: Usually transient, req uiring no special treatment, and does not interfere with the 
subject's daily activities  
• Moderate:  Introduces a low level of inconvenience or concern to the subject and may interfere 
with daily activities, but is usually ameliorated by simple therapeutic me asures  
• Severe:  Significantly interferes with a subject's usual daily activities and requires systemic 
drug therapy or other treatment, if available  
8.3.2 Relationship to Study Treatment  
The causal relationship to study drug or treatment will be determined by the  investigator according 
to best medical judgment, as follows: 
• Suspected:  There is a reasonable possibility that the AE is associated with use of the study 
treatment, such as a temporal relationship of the event to study treatment administration, or 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  47 Mati Therapeutics Inc. - CONFIDENTIAL  
 when other drugs, therapeutic interventions, or underlying conditions do not provide a 
sufficient explanation for the observed event 
• Not suspected:  A relationship between the AE and the study treatment can reasonably be ruled 
out based on lack of any temporal rel ationship of the event to study treatment administration, 
or when the subject's underlying condition, medical history, or other therapy provide sufficient explanation for the observed event. 
8.4 Follow- up for Adverse Event Definitions  
Throughout the study to t he final study contact, all AEs will be followed until they resolve or 
become chronic (as judged by the investigator).  
At the final study visit, new AEs, as well as follow -up information for continuing AEs, will be 
recorded in the CRF and source document. If an SAE (defined in Section 8.2.2)  is unresolved at 
the final study visit, it will be followed by the investigator until it resolves or becomes chronic (as 
judged by the investigator).  Follow- up data for such SAEs will be recorded in the source document 
and reported to the safety monitors (refer to Section 8.7.2).  Non-serious ongoing AEs will be 
followed beyond the final study visit at the discretion of the investigator and recorded in the source documents.   
8.5 Pregnancy Follow -up 
If a subject becomes pregnant during the study, the investigator must inform the Sponsor and 
collect follow -up data regarding the pregnancy, birth, and status of the child. The Sponsor will 
provide special CRFs for data collection in the case of pregnancy.  Follow- up should be continued 
until study close -out at the study site . After close -out, the Sponsor's Safety designee will continue 
to obtain follow-up information. 
Pregnancy should be recorded as a protocol deviation. Pregnancy is not an AE; however, any 
complication related to pregnancy would be considered an AE. 
8.6 Reporting of Technical Complaint  
8.6.1 Definitions  
A quality complaint is one that is received in writing, electronically, or orally that involves the use 
or attemp ted use of a Travoprost Evolute
® plug that identifies any defect in the physical properties 
of the drug product (color, precipitates, viscosity, etc.) or its packaging. Technical complaints also 
include any identified customer dissatisfaction with the physical characteristic(s) of the study product (dispensing characteristics, labeling, packaging, etc.). 
8.6.2 Reporting of Technical Complaints 
Any technical complaint should be reported by fax to the Sponsor's Chief Scientific Officer 
(contact information below) within 24 hours. The complaint report should include the following 
information: 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  48 Mati Therapeutics Inc. - CONFIDENTIAL  
 • Name of the study product 
• Strength of study product 
• Batch/lot number of study product 
• Investigator name, study site name, and contact number 
• Date the complaint occurred  
• Brief de scription of the complaint 
• Identity of any other investigational or commercial devices involved. 
• Study subject or another individual involved (yes/no):  
o If yes and a study subject, the investigator should report whether any AEs were associated 
with the complaint (yes/no;  if a subject AE was associated with the complaint, refer to 
Section s 8.6 & 8.7 and attach the AE CRF page to the complaint) 
o If yes and another individual, the investigator should describe the situation and any ill 
effects on the health of the individual 
o If no, in the investigator's judgment, the investigator should report whether the complaint could reasonably cause an SAE if it recurred under circumstances that did involve a study subject or other person (yes/no). 
The study product and associated packaging that initiated the complaint should be returned to the 
Chief Scientific Officer (address below) for analysis.  
Mati Therapeutics Inc.  
Attn: Chief Scientific Officer  
Deepank Utkhede  
201 – 4475 Wayburne Drive Burnaby, BC  
Canada V5G 4X4  
Fax: 604.637-8747 
Phone: 778.991-3301 
Any complaint about a study product must be reported regardless of whether the defect or deficiency had any effect on a subject or on study personnel. 
8.6.3 Punctal Plug Delivery System Serious Adverse Events and Technical Complaints 
The Sponsor will evaluate all SAE reports and technical complaints received in the study to 
determine if the report meets the definition of an unanticipated A DE. Unanticipated A DEs are 
defined  as follows: 
• Any serious adverse effect on the health or safety or any life- threatening problem or death 
caused by, or associated with, a device, if that effect, problem, or death was not previously 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  49 Mati Therapeutics Inc. - CONFIDENTIAL  
 identified in nature, severity, or degree of incidence in the investigational plan or application 
or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of a subject.  
If the Sponsor determines that any SAE or technical report is an unanticipated A DE, an  
investigation will begin  immediately.  The Sponsor will inform the investigator of any additional 
reporting requirements beyond those stated in Section s 8.6 & 8.7 as applicable.  
If the Sponsor determines that an unanticipated A DE presents an unreasonable risk to a subject, 
the Sponsor will terminate the study as soon as possible. Termination will occur no later than five working days after the Sponsor makes this determination and no later than 15 working days after the Sponsor first received notice of the effect. The Sponsor will report the results of any investigations to the FDA and to investigators, who will also submit the reports to his/her IRBs, within 10 working days after the Sponsor first received notice of the effect.  
8.6.4 Anticipated Adverse Event 
The following is a list including, but not limited to, ocular adverse events that are anticipated.  Any 
event that is unlikely but anticipated must have an adverse event form completed and reported to 
Mati Therapeutics Inc. ( Section 8.7 for reporting details).  
Listing of Anticipated Ocular Adverse Events  
DRUG :  
Incidence rate 30 -50%:  Hyperemia  (*Hyperemia in IZBA controlled studies noted at 12%)  
Incidence rate 5 -10%:  Decreased VA, Eye Discomfort, Foreign Body Sensation, Pain, Pruritus  
Incidence rate 1 -4%: Abnormal Vision, Blepharitis, Blurred Vision, Cataract, cells, 
Conjunctivitis, Corneal Staining, Dry Eye, eye disorder, Iris 
Discoloration, Keratitis, Lid Margin Crusting, Ocular Inflammation, 
Photophobia, Subconjunctival Hemorrhage, Tearing  
DEVICE : 
The main risks of commercial s ilicone punctal plugs are ocular discomfort, epiphora (watery 
eyes), loss of plug (extrusion), ocular inflammation, and subconjunctival hemorrhage. Less 
common, but serious, side effects include but are not limited to pyogenic granuloma, damage to 
the muscle at the opening of t he punctum, canaliculiti or migration of the plug into the canalicula 
(requiring irrigation or surgery)  
NOTE:  Patient treated with an ophthalmic solution of travoprost should be informed of the 
potential for increased brown pigmentation of the iris, periorbital and/or eyelid 
tissue, and increase growth of eyelashes in the treated eye  
8.7 Reporting Procedures  
AEs/ADEs that occur from Visit 2 through completion of the end -of-study visit must be 
documented. The Investigator will assess the AE/ADE severity and relationship to the travoprost 
Evolute®. The Investigator will follow the progress of the study subject until the AE/ADE either 
resolves or becomes medically stable. Treatments and medications required for treatment must be recorded.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  50 Mati Therapeutics Inc. - CONFIDENTIAL  
 All AEs/ADEs, regar dless of severity and whether or not attributed to the drug delivery device are 
to be reported to Mati Therapeutics Inc. AEs/ADEs are also to be reported to the site IRB per the 
IRB’s reporting requirements.  
8.7.1 Adverse Event Reporting 
For each reported AE, investigators should record the following on the appropriate CRF and in the 
subject’s source documents: whether an AE is serious (yes/no), the date of onset, date resolved (date or ongoing), duration (minutes/hours/days), frequency (single/intermittent), se verity 
(mild/moderate/severe), relationship to study treatment ( suspected/not suspected), and if treatment 
was required (medication prescribed, stopped treatment, etc.). 
An adverse event that is not serious or related to the study drug or drug delivery device is to be 
reported to the designated Medical Monitor within 10 working days of the Investigator first becoming aware of the event.  Notification will occur by recording on the appropriate CRF(s), 
scanning and email or faxing the CRF(s) of the visit in which the event is first noted. An adverse 
event is also to be reported to the reviewing IRB/IEC per their reporting requirements. 
8.7.2 Serious Adverse Event Reporting 
Any severe, serious or unexpected AE occurring during or within 15 days after the completion of 
the study, regardless of cause(s) or relationship to the study drug or the drug delivery device , an 
initial report must be made immediately (within 24 hours)  once becoming aware of the event by 
telephone, facsimile, or email to the study Medical Monitor, Robert Williams, MD or the Study 
Monitor, Daniel Schwob (see contact information below).  
The Investigator must complete an SAE Report Form and send it with other relevant pages of the 
CRF to the designated Medical Monitor within 24 hours of the initial discover y of the event . The 
Investigator will also compile with urgent priority other relevant documentation (copies of test results, hospital discharge summary, autopsy report, etc.) and send this information to the 
designated Medical Monitor. Any SAE will be reported to the Investigator’s IRB/IEC per their 
reporting requirements. 
All SAEs will be reported to: 
Robert Williams, MD  Daniel Schwob (back up contact) 
Medical Monitor Study Monitor 
Mati Therapeutics Inc.  D’Ellis Group, Inc. 
email: iopdoc1@gmail.com email: dschwob@dellisgroup.com 
Phone: (Office):  360.378-7916 Phone: (Office):  949.916-2800 
Phone: (Cell)  360.298-5325 Phone: (Cell)  949.735-1320 
Fax:  360.282-6871 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  51 Mati Therapeutics Inc. - CONFIDENTIAL  
 8.7.3 Unanticipated Problem Reporting 
If during the study an adverse event occurs that may reasonably be regarded as study drug and/or 
study- device- related and was not previously expected in nature, severity, or degr ee of incidence in 
the investigation plan, the Investigator is to report the unanticipated adverse event to the designated Medical Monitor within 48 hours, and to the Investigator’s IRB as soon as possible, but no later than 10 working days, after learning of the event as required by 21CFR812.  
8.7.4 Events of Special Interest  
Not Applicable 
8.8 Halting Rules  
Collaboration between representatives of Mati Therapeutics Inc., Investigators and statisticians 
may stop the study if there is evidence of a lack of safety or efficacy associated with the study drug/device or if there is sufficient evidence of efficacy to warrant phase III testing.  
8.9 Safety Oversight 
This study will utilize a Medical Monitor for safety monitoring. The Medical Monitor will review and assess any rep orts of adverse events /adverse device events  and, if necessary, to discuss these 
with the reporting Investigator(s). The medical monitor will also be available to answer all questions from Investigators. 
9 CLINICAL MONITORING  
Mati Therapeutics Inc. represent ative will ensure that the investigation is conducted in accordance 
with the following:  
a. GCPs as specified in ICH E6 (R 2) and E8 (8.2) and 21 CFR. Parts 50, 54, 56, 312 and 812 
b. The signed Investigators' Agreement 
c. The signed IRB approved protocol for the study 
d. Any conditions imposed by the IRB 
e. The requirements of the regulations for the Protection of Human Patients (21CFR50) and all 
other applicable regulations 
Prior to initiation of the study at a site, a Mati representative will conduct a visit with the 
Investigator(s) and the study staff to ensure the following 
a. The Investigator understands the investigational status of the study material and the 
requirements for its accountability  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  52 Mati Therapeutics Inc. - CONFIDENTIAL  
 b. The Investigator understands the protocol and understands and accepts his/her obligations in 
conducting the clinical investigation  
c. The Investigator has adequate facilities for conducting the study, and equipment and instrumentation required by the protocol 
d. The Investigators and his/her staff have sufficient time and access to an adequate number of 
subjects to conduct the clinical investigation. 
During the course of the investigation, a Mati representative may conduct periodic site visits and 
maintain telephone contact with the Investigators and his/her staff to verify  that the stu dy is being 
conducted in accordance with the protocol, and with any specific conditions of the IRB and clinical 
requirements.  At such visits, a Mati representative will: 
a. Verify that informed consent has been obtained and documented for each study subject, in 
accordance with 21 CFR parts 50 and 56, and the requirements of the overseeing IRB and the 
Sponsor.   
b. Review and compare CRFs to source records and supporting documents to ensure that data 
recorded on the CRFs are complete, accurate, and legible  
c. Verify  that any corrections to the CRFs are made with a single line strike -through of the 
incorrect entry, and entry of the correct information adjacent with initials of the individual making the correction and date of corrected entry  
d. Verify  that there are no dat a omissions and that any study subject withdrawals are 
documented.   
e. Review CRFs and source records for any unanticipated AE s/ADE s, and ensure that the 
Investigators are complying with FDA and Sponsor requirements for reporting AEs /ADEs  
and SAEs /SADEs .   
f. Verify  that the Investigator (s) is carrying out the agreed upon activities and ha s not delegated 
them to unauthorized staff  and that the facilities and staff continue to be acceptable for the 
study. 
g. Verify the Investigator (s) is properly tracking study inventory and is accounting for the 
disposition of all study devices. 
h. Prepare and maintain records of each site visit, significant telephone discussion, and written 
communications with the site. These records will include such information as: 
i. Date, name, and address of the Investigator (s) and names of other staff members present 
at each meeting  
ii. A summary of the findings of the visit  
iii. A statement of any action taken by a Mati representative or Investigator (s) to correct any 
deficienci es noted. 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  53 Mati Therapeutics Inc. - CONFIDENTIAL  
 10 STATISTICAL CONSIDERATIONS  
10.1 Statistical and Analytical Plans 
The primary analysis population will be an ITT (Intent -to-Treat) analysis for all study subjects 
who had the lower puncta of each eye inserted with a study punctal plug and had no major protocol 
violations. Individual study subjects or individual visits may be excluded if a major protocol 
violation occurs (such as violation of inclusion/exclusion criteria or non- compliance with protocol 
requirements that can potentially have significant i mpact on study outcomes).   
10.2 Statistical Hypotheses  
The Null Hypothesis:  There are no differences between baseline and follow -up visit intraocular 
pressure values  
Alternative Hypothesis:  There are differences between baseline and follow -up visit intraocular 
pressure values  
10.3 Analysis of Datasets 
Data will be pooled from all study sites for data analysis, unless otherwise specified.  Study dataset 
will be generated (keypunched) from original (white) case report forms (CRFs) that have been 
reviewed and collected from clinical sites.  Dataset will contain rows of individual subject data; 
each row will be clearly labeled with the study subject assigned study  number and initials. Each 
column of the dataset will contain a specific parameter for all study subjects.   
10.4 Description of Statistical Methods  
10.4.1 General Approach  
Descriptive statistics (i.e., mean, standard deviation, etc.) will be provided for all continuous 
variables and frequency distributions will be generated for all categorical variables collected in this study.  Analyses of the intent -to-treat (ITT) data set, will include all data from all subjects with 
a recorded screening visit IOP OU.  Per protocol (PP) analyses dataset, will exclude data from 
subjects or visits with significant protocol deviati ons (e.g., IOPs obtained before 8:00 AM and 
after 10:00 AM will be excluded). 
10.4.2 Analysis of Primary Study Variable  
The primary study outcome variable will be the change in IOP at Visit s 4, 5, 6 and 7 (Day s 7, 28, 
60 and 90 days post -insertion) compared with the Baseline IOP (Visit 2, Day 0 ), obtained between 
8:00 and 10:00 AM . The unit of analysis will be the study eye  at visit 2 with the highest post-
washout IOP . Observed IOP and percent change from baseline in IOP will also be analyzed. 
10.4.3 Other Data Endpoints 
The following will be evaluated:  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  54 Mati Therapeutics Inc. - CONFIDENTIAL  
 - Mean and percent change in Baseline IOP (post -washout) compared with Screening IOP (pre -
washout)  
- Mean and percent of patients screened vs patients that qualified for the study washout phase 
- Mean and percent of patient entered in the washout phase that qualified for the treatment phase  
- Evaluate enrollment rate of patients in to the various phases of the study (avg. number of 
patients by day/week/month)  
- Mean and percent of patients and eyes with IOPs > 34 mmHg post-washout - Mean and percent of patients and eyes that extruded a plug during the study treatment phase - Mean and percent of patients and eyes the investigator was unable to dilate to at least 1.0 mm - Mean and percent of patients and eyes the investigator was unable to insert with a Travoprost 
Evolute
® 
- Listing of reasons why patient failed to qualify for various phases of the study 
10.4.4 Safety Analyses  
All subjects that qualify for the washout phase of the study will be evaluated. Safety variables will 
include any clinically significant changes in IOP, BCDVA, slit -lamp findings, ocular tearing and 
comfort, blood pressure, heart rate, temperature, study p lug inspections/extrusions, and incidence 
and severity of any reported AEs/SAEs  and ADEs/SADEs .   
10.4.5 Adherence and Retention Analyses  
Not Applicable 
10.4.6 Baseline Descriptive Statistics  
Demographic and baseline characteristics will be summarized. Counts and percentages will be 
presented for categorical variables such as gender , age group (by decade), race and ethnicity.  
Mean, standard deviation, median, minimum and maximum will be presented for continuous variables such as age and  non-dilated punctum size. 
10.4.7 Planned Interim Analyses  
Data will be analyzed on an ongoing basis. The final analyses will be completed after the last study subject has completed his/her final visit and the study database has been closed. 
10.4.8 Tabulation of Individual Response Data 
Not Applicable 10.4.9 Exploratory Analyses 
Not Applicable 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  55 Mati Therapeutics Inc. - CONFIDENTIAL  
 10.5 Sample Size  
Since this is a pilot study, no formal sample size estimation will be performed.   
10.6 Measures to Minimize Bias  
Not Applicable. 
10.6.1 Enrollment 
Each investigational site will be assigned a site ID number (e.g., 100, 200 . . . 500). As a potential 
study subject qualifies to enter the study washout period, they will be sequentially assigned a study number that corresponds with the site ID number (e.g., 101, 102, . . . 110). If the potential subject does not qualify after the washout period, the subject ID number will be retired. Those subject s 
that do qualify will be identified throughout the treatment period of the study by his/her assigned 
subject ID number and initials . 
10.6.2 Evaluation of the Success of Blinding/Masking Tr eatment  
Not Applicable 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DAT A/DOCUMENTS  
11.1 Source Documentation  
The Investigator must maintain adequate and accurate source documents upon which CRFs for 
each study subject are based.  They are to be separate and distinct from the CRFs, except for cases 
in which the Sponsor has predetermined that direct data entry into specified pages of the subject's CRF is appropriate. Study source documents should include detailed notes on: 
a. Study protocol number 
b. The oral and written communication with the study subject regarding the study treatment 
(including the risks and benefits of the study).   
c. The date that informed consent and HIPAA forms were signed must be recorded in the source documentation 
d. The study subject's medical history prio r to participation in the study 
e. The study subject's basic identifying information, such as demographics, that links the subject's source documents with the CRFs 
f. Date of all study subject visits throughout the duration of the study 
g. Date the punctal plug was  first inserted, removed and if applicable, dates of any plug that was 
extruded/loss and a new plug was re- inserted  
h. Intraocular Pressure values  and slit-lamp findings at each visit  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  56 Mati Therapeutics Inc. - CONFIDENTIAL  
 i. The subject's exposure to any concomitant therapy (including start and stop dates, route of 
administration, and dosage) at each visit 
j. Blood pressure, temperature and heart rate values at each visit  
k. All reported AEs /ADEs  and SAEs /SADEs  
l. All relevant observations and data on the condition of the subject throughout the study 
11.2 Access a nd Retention of Study Records  
The study is subject to audits by the Sponsor/designee, third parties, or by regulatory authorities. 
If such an audit occurs, the Investigator must agree to allow access to all required study subject records.  The Investigator will notify Sponsor promptly of any FDA audits that are scheduled, and 
must forward copies of any resultant Form 483 and/or audit reports to the Sponsor promptly. 
All study records will be maintained by the Investigator at the site for a minimum of 2 years 
following the date a marketing application is approved for the drug for which the indication was being investigated. If no application is to be filed or the application is not approved for such 
indication, study records must be retained f or at least 2 years after the investigation is discontinued 
and the FDA is notified. 
11.3 Subject Confidentiality  
All records identifying the study subject by name will be kept confidential.  The Investigator will 
ensure the study subject’s anonymity is maintained throughout the course of the study. A study 
subject will be assigned a site/subject ID number to maintain study subject confidentiality.  In 
particular, the Investigator will keep an enrollment log with confidential identifying information 
that c orresponds to the subject numbers and initials of each study subject.  A study subject name 
may possibly be disclosed to Mati Therapeutics Inc. or regulatory agencies during inspection of medical records related to the study, but reasonable precautions will  be taken to maintain 
confidentiality of personal information to the extent permitted by applicable laws and regulations.  
If the results of the study are published, the study subject’s identity will remain confidential. 
11.4 Case Report Form Completion  
The Inve stigator is responsible for ensuring that data are properly recorded on each study subject’s 
case report forms and related documents.  An Investigator who has signed the protocol signature 
page should personally sign completed case report forms to ensure that the observations and 
findings are recorded on the case report forms correctly and completely.  Following study 
examination, investigative sites should complete and remove the yellow NCR copy of the CRF from the study subjects’ booklet leaving the white copy of the CRF intact inside the booklet. Yellow copies of completed CRFs will be mailed in on a we ekly basis to the following: 
D’Ellis Group, Inc. 
Attn: Daniel Schwob  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  57 Mati Therapeutics Inc. - CONFIDENTIAL  
 26741 Portola Pkwy, 1E 717 
Foothill, Ranch, CA  92610 
The white copy of the CRF data will be reviewed against the subject’s source data by the study 
monitor(s) to ensure completeness and accuracy. After monitoring has occurred at the clinical 
site(s) and the CRFs have been submitted, additional data clarifications and/or additions may be needed.  Data clarifications and/or additions are to be documented and will be part of each subject’s 
CRFs.  
11.5 Investigator Study Summary  
A final Investigator’s summary will be provided to Mati Therapeutics Inc. within approximately three months after the completion of the study. The Investigator summary should include: 
a. Investigator name and title  
b. Title of the protocol 
c. Date the clinical study began (1st enrolled study subject) and the date the last study subject 
exited the study  
d. Number of study subjects enrolled into the study, completed, discontinued, terminated, withdrew 
e. Brief discussion regarding any reported AEs/SAEs and ADEs/SADEs  
f. Brief discussion of clinical findings during the study. 
12 QUALITY ASSURANCE AND QUALITY CONTROL  
Investigator must grant permission to personnel from the Sponsor, its representatives, third parties 
and appropriate regulatory authorities for on -site monitoring and review of all appropriate study 
documentation, as well as on- site review of the procedures employed in data collection, where 
clinically appropriate.  Study auditing, data entry, verification and validation, and subsequent 
analysis will be performed by the Sponsor or Sponsor’s designees in accordance with GCPs and 
established Standard Operating Procedures. 
13 ETHICS/PROTECTION OF  HUMA N SUBJECTS  
13.1 Ethical Standard  
The Investigator agrees to conduct the study in accordance with United States Investigational New 
Drug regulations specified under 21 CFR 11, 50, 54, 56, and 312, the International Conference on Harmonization (ICH) Harmonized Tr ipartite Guideline for Good Clinical Practice (GCP), and the 
Guidelines of the Declaration of Helsinki, Finland, 1964 and its subsequent amendments (Tokyo, Japan, 1975; Venice, Italy, 1983; Hong Kong, 1989; Republic of South Africa, 1996; Scotland, 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  58 Mati Therapeutics Inc. - CONFIDENTIAL  
 2000). The Investigator will conduct all aspects of the study in accordance with all national, state, 
and local laws of the pertinent regulatory authorities. 
13.2 Institutional Review Board 
The protocol, Informed Consent Form (ICF), and any study subject information s heet must be 
approved in writing by the appropriate IRB before the study can be initiated at a site. A copy of 
the IRB approval must be sent to the Sponsor (or designee) along with a list of the IRB members 
and their occupations/affiliations. Institutional Review Board approval is also required for any 
advertising or other material used for subject recruitment.  If the protocol is amended, the 
Investigator must sign the revised protocol and submit the amendment to the IRB for review and approval prior to implementation of the changes specified in the amendment.  The Investigator 
must report promptly to the IRB all changes in the research activity and all unanticipated problems involving risk to human subjects or others, including all SAEs /SADEs  that have resul ted in an 
expedited safety report to the FDA.  No drug will be shipped to a site until IRB approval has been 
granted and the Sponsor or designee has been notified of this in writing. 
The Investigator is responsible for obtaining continued review of the clinical study, at intervals not 
to exceed 1 year or otherwise specified by the IRB.  The Investigator must provide the Sponsor (or 
designee) with written documentation of the continued review. 
13.3 Informed Consent Process  
13.3.1 Consent Procedures and Documentation  
Each subject must provide written Informed Consent before any study -related procedures are 
started.  It is the responsibility of the Investigator or designated staff member(s) to give a copy of 
the Informed Consent to each potential study subject and to be available to answer any questions 
the subject may have about the nature of the study and his or her participation in it. The individual 
responsible for explaining the consent form to the subject must witness the subject’s signature on the form.  It is the respon sibility of the Investigator to provide a copy of the IRB -approved consent 
form to the Sponsor (or designee) prior to the start of the study. If a protocol amendment 
substantially alters a study design or increases the potential risk to the study subject, the consent form must be revised and submitted to the IRB(s) for review and approval prior to implementation. The revised consent form must be used to obtain consent from each study subject currently in the study if they are affected by the amendment and f rom new subjects prior to enrollment in the study.  
13.3.2 Other Informational Documents Provided to Participants 
A subject to be enrolled in to the study is required to review and sign a Health Insurance Portability and Accountability Act (HIPAA) of 1996 authorization document. Each study subject will receive 
copies of all applicable informational documents for his/her records.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  59 Mati Therapeutics Inc. - CONFIDENTIAL  
 13.4 Participant and Data Confidentiality 
Any party (e.g., domestic and foreign regulatory authorities, sponsor's monitors and auditors) with 
direct access will be required to take all reasonable precautions within the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of subjects' identities and sponsor’s proprietary information. 
The confidentiality of records that could identify  a subject will be protected, respecting the privacy 
and confidentiality rules in accordance with applicable regulatory requirement(s). 
13.4.1 Research Use of Stored Human Samples, Specimens or Data  
Not Applicable 
 
14 DATA HANDLING AND RE CORD KE EPING  
14.1 Data Collection and Management Responsibilities 
The nature and location of all source documents will be identified to ensure that original data 
required to complete the CRFs exist and are accessible for verification by the site monitor.  At a 
minimum,  source documents should include specific data, as indicated in Section 11.1 (source 
documentation) of the protocol, for each subject. 
14.2 Study Records Retention  
The Investigator must arrange for retention of study records at the site for 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the formal discontinuation of clinical development of the study drug/device. These documents should 
be retained for a longer period, however, if required by the applicable regulatory requirements or by agreement with the Sponsor. The Sponsor will inform the Investigator/Institution as to when 
these documents no longer need to be retained. The Investigator will take measures to prevent any 
accidental or premature destruction of these documents.  
a. All adverse event information (adverse event forms, follow- up letters, etc.)  
b. Study subject records (source documents/CRFs) 
c. Investigational supply records/inventory 
d. IRB and regulatory approval documentation 
e. All study related correspondence  
f. All study agreements  
g. Site visit documentation  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  60 Mati Therapeutics Inc. - CONFIDENTIAL  
 h. Protocols and the reason for any deviations from the protocol 
i. Study Subject log 
j. Clinical Investigator’s Brochure 
k. Completed study subject informed consent and HIPAA forms 
l. Study subject medical chart/clinic notes.  
It is required that the author of an entry in the source documents be identifiable. Direct access to 
source documentation (medical records) must be allowed for the purpose of verifying that the data 
recorded on the CRF are consistent with the original source data.  
NOTE : These documents should be retained for a longer period if required by the applicable regulatory requirements  or by agreement with the Sponsor. It is the 
responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. The Investigator should take measures 
to prevent any accidental or premature destruction of these documents. 
Mati Therapeutics Inc. requires notification if the Investigator wishes to relinquish ownership of the data so that mutually agreed -upon arrangements can be made for transfer of ownership to a 
suitably qualified, responsible person. 
14.3 Protocol Deviations 
Any deviation from the protocol done to protect the life or physical well -being of a study subject 
in an emergency must be reported to Mati Therapeutics Inc. and the reviewing Institutional Review 
Board (IRB) as soon as possible, but no later than five working days after the deviation occurs. Unless it is an emergency, if the Investigator desires to modify any procedure and/or deviate from the design of the study, he or she must contact and obtain consent from Mati Therapeutics Inc.  
regarding the proposed changes prior to implementation. If the modifications may affect the 
scientific soundness of the study, or the rights, safety, or welfare of the study participants, approval by the FDA and all appropriate regulatory agencies as well as  approval of the IRB is also required  
(refer to Section 13.2 for details).  
14.4 Publications and Data Sharing Policy 
All information related to this study is considered confidential information belonging to Mati Therapeutics Inc.  Data on the use of the study drug/device and results of all clinical and laboratory 
studies are considered private and confidential. None of the details, results, or other information 
for this study shall be published or made known to a third party without written consent from Mati Therapeutics Inc., except for disclosure to regulatory agencies if required by law.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  61 Mati Therapeutics Inc. - CONFIDENTIAL  
 15 LITERATURE REFERENCE S 
Bengtsson B, Heijl  A. 2005. A long- term prospective  study of risk factors  for glaucomatous  
visual field  loss in patients  with  ocular  hypertension. J Glaucoma.  14(2):135-138. 
Choy BNK et al. 2019. Factors Associated with Poor Eye Drop Administration Technique and 
the Role of Patient Education among Hong Kong Elderly Population. Journal of Ophthalmology, 
vol. 2019, Article ID 5962065, 5 pages. 
Gordon MO, Beiser  JA, Brandt  JD, et al. 2002. The Ocular  Hypertension Treatment  Study: 
baseline factors  that predict  the onset  of primary  open- angle  glaucoma.  Arch  Ophthalmol.  
120(6):714- 720. 
Kass  MA, Heuer  DK, Higginbotham  EJ, et al. 2002. The Ocular  Hypertension Treatment  
Study: a randomized  trial determines  that topical  ocular hypotensive medication  delays  or 
prevents the onset of primary  open- angle glaucoma.  Arch  Ophthalmol.  120(6):701- 713. 
Leonard  R. 2002. Statistics  on Vision  Impairment: A Resource  Manual  (5th Edition). New  York:  
Arlene R Gordon Research  Institute  of Lighthouse  International.  
Leske  MC, Heijl  A, Hyman  L, Bengtsson  B, Komaroff E. 2004. Factors  for progression and 
glaucoma  treatment:  the Early  Manifest  Glaucoma Trial.  Curr Opin  Ophthalmol.  15(2):102- 
106.  
Maier  PC, Funk  J, Schwarzer  G, Antes  G, Falck -Ytter  YT. 2005. Treatment  of ocular  
hypertension and open angle  glaucoma:  meta -analysis  of randomised  controlled  trials.  BMJ.  
331(7509):134. Epub  2005 Jul 1. 
Robin AL, Covert D. 2005. Does Adjunctive Glaucoma Therapy Affect Adherence to the Initial 
Primary Therapy? Ophthalmology. 112:863-8 
16 APPENDICES  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  62 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix A  
Page 1 of 2  
GUIDELINES FOR INFORMED CONSENT  
Both the written informed consent form and the discussion of  informed consent with a potential 
study subject should include explanations of the following: 
a. The study involves research 
b. The purpose of the study 
c. The study treatment(s)  
d. The study procedures to be followed, including all invasive procedures 
e. The subject's  responsibilities  
f. The aspects of the study that are experimental  
g. The reasonably foreseeable risks or inconveniences to the study subject and, when applicable, 
to an embryo, fetus, or nursing infant 
h. The reasonably expected benefits.  When there is no intende d clinical benefit to the study 
subject, the study subject should be made aware  
i. The alternative procedure(s) or course(s) of treatment that may be available to the subject, and their important potential benefits and risks 
j. The compensation and/or treatment  available to the study subject in the event of study -related 
injury 
k. The anticipated prorated payment, if any, to the study subject for participating in the study 
l. The anticipated expenses, if any, to the subject for participating in the study 
m. The study subject's participation in the study is voluntary and that they may refuse to participate or withdraw from the study, at any time, without penalty or loss of benefits to which they are otherwise entitled  
n. The monitor(s), the auditor(s), the IRB/Independent Ethics Committee (IEC), and the regulatory authority(ies) will be granted direct access to the study subject's original medical records for verification of clinical study procedures and/or data, without violating the confidentiality of the subject, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent form, the subject or the subject's legally acceptable representative is authorizing such access  
o. The records identifying the study subject will be kept conf idential and, to the extent permitted 
by the applicable laws and/or regulations, will not be made publicly available. If the results of the study are published, the subject’s identity will remain confidential. 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  63 Mati Therapeutics Inc. - CONFIDENTIAL  
 Page 2 of 2  
p. The study subject or their legally acceptable representative will be informed in a timely 
manner if information becomes available that may be relevant to the subject's willingness to continue participation in the study 
q. The person(s) to contact for further information regarding the study and the rights of a study 
subject, and whom to contact in the event of study- related injury  
r. The foreseeable circumstances and/or reasons under which the subject's participation in the study may be terminated  
s. The expected duration of the study subject' s participation in the study  
t. The approximate number of study subjects involved in the study. 
 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  64 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix  B 
HIPAA Form  
PATIENT AUTHORIZATION FOR USE AND RELEASE OF HEALTH AND  
RESEARCH STUDY INFORMATION  
Study Number:  TGLA -2021-01 
Study Title:  A 90-Day, Open -Label, Multi- Site, Pilot Study Evaluating the Safety and 
Intraocular Lowering Effect of Delivering Travoprost using a Punctal 
Plug Delivery System (Evolute®) in Subjects with Elevated Intraocular 
Pressure  
By signing this Authorization, you agree to permit the disclosure of your confidential medical 
information by the Physician and others involved in the research to affiliates, agents and 
contractors (Sponsor) and Regulatory Authorities [e.g., the United States Food and Drug Administration (FDA)] for the purpose of conducting a study on a punctal plug delivery system 
design to deliver a glaucoma medication to your eye and the effect  the medication has on reducing 
the pressure within your eye . Outcomes from this study may include publication of anonymous 
patient data.  Such information may include, without limitation, your initials, age, race and gender.  
The Sponsor has provided financial assistance to the Physician to support these purposes. 
Furthermore, such information may be used, along with medical information of other 
individuals, in the creation and maintenance of a research database or repository for follow -up or 
retrospective research and/or statistical purposes.  Such information may also be transferred to 
another country, which may have different privacy laws. Once your information has been released 
to the Sponsor, it will continue to be protected by the Sponsor’s privacy policy or by privacy policies that, in the Sponsor’s judgments, provide protection that is equivalent to the Sponsor’s 
privacy policy. It will not, however, have the protection of the federal privacy regulations. 
Unless another date is required by applicable law(s) your authorization will NOT expire 
because this information will be compiled into clinical research dat a and used for research purposes 
in the future, and you consent to the retention and future processing of your data. If your 
information is obtained in California, USA, this authorization will expire in 20 years. 
You have the right to revoke this authorization at any time, so long as you do so in writing. If 
you wish to revoke this authorization, please send a letter in which you refer to this authorization by the date of your signature below, to the physician conducting this trial (Doctor’s name and 
addres s listed below).  However, please be advised that your revocation may not be effective if, in 
the meantime, the Physician has taken action in reliance on this authorization. We will honor your 
revocation to the greatest extent possible without diminishing the purposes of the trial. 
You have the right to access your data, subject to reasonable limitations, and to submit 
corrections to the Physician at the address listed below. You understand that you will not be 
allowed access to the information about you if we believe that disclosure of this information would jeopardize the integrity of the research efforts or other purposes of the trial. Following the 
conclusion of the trial, upon your request and under reasonable terms, you may access your 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  65 Mati Therapeutics Inc. - CONFIDENTIAL  
 personal informat ion that we retain.  This information may be most readily available from the 
Physician, but the Sponsor will endeavor to provide you access to your information if necessary. 
The Physician and Sponsor will ensure that reasonable and appropriate physical, procedural, and 
technological safeguards are in place in order to protect your information from inadvertent destruction, disclosure or unauthorized access.  
The Physician may condition your participation in the trial on whether or not you sign this 
authorization or revoke it at a future date.  
One copy of this authorization will be kept by the Physician and the Sponsor may retain another 
copy in their files. You will receive a copy of the authorization that you have signed and dated.  
 
Physician’s Name:  TBD , MD 
 
Address:  TDB (Street 1)  
 TDB (Street 2)  
 City, State   Zip Code 
 
I have read and understand this Authorization, and agree that my medical information 
may be used and released according to the terms written above.  
 
 
____________________________  _______________________________  _______________  
Print Name of Study Subject  Study Subject ’s Signature  Date of Signature  
 
OR 
____________________________  _______________________________  _______________  
Print Name of  Signature of  Date of Signature  
    Legall y Authorized Representative      Legally Authorized Representative  
  
_________________________________________________________________________ 
Indicate Relationship to Study Subject  
   
Acknowledged by Physician 
 
 
____________________________  _______________________________  _______________  
Print Name of Physician  Physician Signature  Date of Signature  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  66 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix C  
Examination Tests/ Procedures  and Equipment  
1. TESTS/PROCEDURES  
a. Blood Pressure and Heart Rate  
Throughout the study, vital signs (blood pressure, heart rate) will be taken with the subject 
in the sitting position after the subject has rested for at least five minutes.  Blood pressures 
may be determined manually with a blood pressure cuff and auscultation or with an automated Blood Pr essure monitor. Heart rates may be determined electronically with an 
automated Blood Pressure monitor. Manually obtained heart rates should be recorded after a 
minimum of 30 seconds of observation. 
b. Temperature  
Temperature maybe taken using a non -contact (Infrared) thermometer or orally. Oral 
temperatures should not be taken within five minutes of ingestion of any food or drink 
c. Visual Acuity  
Best-corrected distance visual acuity will be measured using a Snellen chart while the subject 
is wearing his or her glasses. Pinhole visual acuity will be measured using a Snellen chart 
while the subject is looking through a pinhole occluder. The test distance and lighting conditions specified for the investigator’s chart must be used and kept constant throughout 
the study. 
d. Automated Perimetry  
Full threshold visual fields will be measured using a Humphrey's Visual Field Analyzer 
(manufactured by Carl Zeiss Meditec Inc., Dublin, CA) with at least a standard full -threshold 
24-2 program or Swedish interactive threshold algorithm (SITA) program. Visual fields 
measured up to SIX months  before the Screening Visit are acceptable to fulfill the screening 
procedure. 
e. Pachymetry  
Corneal thickness can be measured by contact methods, such as ultrasound and confocal microscopy (CONFOSCAN), noncontact methods such as optical biometry with a single Scheimpflug camera (such as SIRIUS or PENTACAM), dual Scheimpflug camera (such as GALILEI), or Optical Cohe rence Tomography (OCT), such as Visante.  Corneal thickness 
data that is documented in the patient chart is acceptable to fulfill the screening procedure.  
f. Evaluation of Slit- Lamp Findings (Lids, Cornea, Conjunctiva)  
The severity of a sign will be graded  by the investigator based on the appearance at each 
study visit using the following scale:  
NONE (0) = Normal ;  
TRACE (1) = Slightly visible;  
MILD (2) = Somewhat visible and diffuse;  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  67 Mati Therapeutics Inc. - CONFIDENTIAL  
 MODERATE (3) = Visible and diffuse;  
SEVERE (4) = Extremely visible and  dense 
g. Intraocular Pressure Measurements  
(see Appendix D for details)  
h. Dilated Fundus Examination 
Using an ophthalmoscope, the investigator will examine the back part of the eye (fundus), 
including the retina, optic disc, choroid and blood vessels. 
i. Position Evaluation of the Study Plug 
Study plug position will be evaluated as either: 
• Normal  
• Present but requires adjustment 
• Extruded/Recovered  
• Extruded/Lost 
Othe r 
j. Punctal Measurements  
(see Appendix E  for details)  
k. Adverse Event /Adverse Device Event  
To optimize consistency of AE reporting across centers, the subject will be asked a standard 
question to elicit any AEs. At each study visit or telephone evaluation of the subject, study personnel (non-observer) will ask the following question:   
"Have you had any problems since your last visit?"  
2. EQUIPMENT  
a. Coroneo Punctal Gauge 
Description  
The Coroneo Punctal Gauge ( Figure 5) is designed to aid the physician in determine the size 
of the punctum. In addition, the instrument provides a simple and controlled method for 
punctal dilation prior to plug insertion. 
The system consists of a single handpiece, with gauging and dilation marks at each end. The 
instrument is manufactured from medical grade Titanium, and is autoclavable. A ll Coroneo 
Gauges are shipped with tip protectors which must be removed before use, cleaning, 
disinfecting, or sterilizing.  
For proper measurement and insertion of punctal plugs, the following procedures are 
recommended. A topical anesthetic for the punctum is recommended before proceeding with 
the use of this instrument. ALWAYS measure the punctum first before dilation . See 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  68 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix E  for procedure s to gauge the size of a punctum and Appendix F  for procedures 
to dilate the punctum to at least 1.0 mm.   
 
Cleaning, disinfection and sterilization of punctal gauge 
Prior to use, the Punctal Gauge should be examined for damage and wear 
NOTE : The Coroneo Punctal Gauge is intended to contact mucous membranes only. 
Instruments that contact mucous membrane only, may have high level 
disinfection, as specified by the Center for Disease Control (CDC) and the AAMI 
Technical Information Report 12 (TIR 12). Instruments used under other 
conditions may require steriliza tion. 
i. Cleaning Instructions  
 Punctal gauge is to be kept moist, after usage and until cleaning is completed  
 Fresh water and an enzymatic detergent (e.g., Enzol®) are the cleaning agents  
 Punctal gauge is cleaned by soaking, coupled with brushing with a soft bristled brush, 
such as a toothbrush. Brushing should be done underwater to prevent aerosolizing 
of microorganisms  
 After cleaning, rinse the punctal gauge with a stream of fresh water.  
ii. Disinfecting Instructions  
 Soak the  punctal gauge in a liquid chemical germicide solution labeled as a 
disinfection/sterilant (e.g., Cidex®) which has been approved by a competent 
authority for use in disinfecting or sterilizing medical instruments  
 Soak the  punctal gauge for the time listed by the manufacture of the disinfection/sterilant 
solution  
NOTE:  Disinfection/sterilant solutions are alkaline (e.g., high pH) and will affect anodized instruments. Do not leave anodized instruments in these solutions 
for a protracted period of time. 
 After disinfection, rinse instrument with a stream of fresh water, and dry completely  
iii. Sterilization Instructions  
 If the punctal gauge is placed in a sterilizing tray, do not allow the punctal gauge to 
touch other instruments or the sides of the tray  
 After sterilization,  if the punctal gauge is not intended for immediate use, gauge must 
be wrapped in an appropriate material such as a pouch to maintain sterility  
 Chemical and biological indicators should be used to verify sterilization  
 Steam steriliz ation has been validated for 15 minutes, gravity cycle at 270oF (132oC). 
 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  69 Mati Therapeutics Inc. - CONFIDENTIAL  
 b. Castroviejo Corneal Suturing Forceps  
Description  
Castroviejo Corneal Suturing Forceps are designed for handling both corneal tissue and 
suture materials during eye surgery procedures. Castroviejo Corneal Suturing Forceps have 
tying platform with Tungsten Carbide dust for additional grip and reliability.  
Manual disinfection  
Due to the potential for residual chemicals to remain on the instrument and cause an adverse 
reaction, do not use an enzymatic or liquid chemical disinfectant or sterilant when manually 
cleaned instrument.  
Drying  
Dry the instrument with a lint- free surgical wipe or blow the instrument dry with micro -filtered 
pressurized medical grade air. When blowing dry with pressurized air, ensure a secure grip on the 
instrument to avoid damage to the instrument from air pressure. 
Maintenance, Inspection and Testing  
Following cleaning, inspect the instrument to ensure that all visible soil has been removed and that 
the instrument operates as intended. A microscope should be used whenever possible.  
Packaging  
Package the instrument in a suitable sterilization pouch or instrument tray lined with soft silicone 
mats. Protective tips made of soft silicone of the proper size an d thickness are recommended. 
Instruments should not be touching each other. 
 
 
  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  70 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix D 
Procedure for Performing Applanation Tonometry  
Goldmann applanation tonometry will be used for measuring the intraocular pressures (IOP) of 
each eye. Just prior to the start of the study, the tonometer should be calibrated  and at least 
once every month  during the duration of the study . 
Accurate and precise IOP readings are imperative, studies have found tight collars, ties or other 
restrictive clothing around the neck may cause an increase in venous pressure when the patient 
extends his or her neck forward, resulting in an inaccurately high IOP reading. Have a patient 
loosen any collars or neckties that may be restrictive to obtain an accurate measuremen t. 
The IOP of each eye will be measured by a qualified evaluator [Study investigator, Co-
investigator(s) or Sub- investigator(s)].  If there is more than one evaluator in the office, the same 
individual and the same Goldmann applanation tonometer used to mea sure the screening IOPs 
should be used to take measurements at all study visits.  
NOTE:  Study subjects IOP measurements must be evaluated between 8:00 and 10:00 AM  
Measuring and Recording of IOPs  
A topical anesthetic will be instilled on each eye. Afterwar ds a fluorescein strip or drop will be 
placed onto the cul -de-sac of each eye. The IOP will be measured by the evaluator  by placing the 
applanator tip on the corneal apex. When the evaluator  has obtained a desired endpoint (i.e., mires 
of equal size, centered in the field, with the inner surfaces of the circles "kissing" ), the tip can be 
withdrawn from the cornea ( Figure 4-B). 
Figure 4 
Applanation tonometry semi- circles viewed through the Gol dmann Prism  
A B C 
   
Correct end point :(diagram “B”):  
Inner  edges of the semi -circles  
are just touching  (“kissing”)  
After the tonometer has been withdrawn, read and record the pressure from the scale on the knob 
on the side of the tonometer, then reset the tonometer knob to "10" (NOTE: Whenever possible,  

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  71 Mati Therapeutics Inc. - CONFIDENTIAL  
 the same individual should perform  and record the pressure values from the tonometry, at each 
time point for all subjects).  
 
The IOP of each eye will be measured twice, alternating between eyes. However, if the second 
measurement is > ± 3 mmHg  from the first measurement for an eye, a third measurement will be 
taken. All measurements taken will be recorded. In the case of two measurements, the average of 
the two values will be used for analysis, and in the case of three measurements, the average of the two closest values of the three will be used for analysis for that eye at that specific time point.  
 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  72 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix E  
PROCEDURE FOR GAUGING (MEASURING) PUNCTUM SIZE  
The Coroneo Punctal Gage  (Figure 5) is a reusable double -ended instrument that allows you to 
gauge the size of the puncta from 0.5 mm to 1.0 mm. Do not dilate the punctum before gauging 
the size of the punctum. 
Figure 5 
Coroneo Punctal Gage  
 
 Expanded view of the 
punctal gauge tips  
 
NOTE : Care should be taken when gauging the punctum  not to perforate the punctal 
sphincter . If the size of the study subject puncta has not be measured, gauge) the 
size of each punctum prior to dilating.  
1. The study subject may be seated at the slit-lamp or placed in a reclined position 
2. Anesthetize the area around the lower punctum  
NOTE : Placing a drop of topical anesthetic such as proparacaine or lidocaine on 
the eye to be inserted. Then adding lidocaine gel on a cotton- tipped swab 
and placing the swab directly on the lower punctum of the eye for 5 seconds and wait a few minutes . Past investigators have found this to be effective 
in numbing the area around the lower punctum 
3. Use slight finger traction to expose and stabilize the punctum 
4. Begin with the smallest gauge tip (0.5, 0.6, 0.7) of the Coroneo gage  
5. Gently insert the tip of the gauge in to the punctum vertically  
6. Once the horizontal canaliculus has been reached,  if necessary, gently turn the instrument 
horizontally to continue inserting past the vertical canaliculus.   
7. If the instrument can be inserted past the third ring on the tip of the Coroneo gage  without 
observing tightening of the punctal ring – stop and  remove the gauge  
8. Repeat the above procedure using the larger end of the Coroneo gage  (0.8, 0.9, 1.0) 
9. When tightening of the punctal ring is observed around the instrument read the appropriate 
size from the gauge.  There are three “grooves” in each en d of the gauge that correspond 
to the three sizes indicated on the handle  
10. Record the punctal size in the appropriate section of the case report form.  
If gauging the size of the punctum is immediately followed by dilating and inserting the study 
plug (PPDS), refer to Appendix F for details regarding the dilation of the lower punctum.    

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  73 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix F  
 
PROCEDURE FOR DILATION OF THE PUNCTUM  
Use the C oroneo Punctal Gage ( Figure 5) to dilate the punctum. If the size of the study subject 
puncta have not be en measured , gauge  (Appendix E ) the size of each  punctum prior to dilating . 
NOTE : Care should be taken when dilating the punctum not to perforate the punctal 
sphincter .  Dilating and inserting the punctal plug delivery system (PPDS) 
should be performed on ONE  eye at a time . 
1. The study subject may be seated at the slit- lamp or placed i n a reclined position. The 
following s teps 1 -6 are the same procedure used to measure (gauge) the size of the 
punctum 
2. Anesthetize the area around the lower punctum  
NOTE : Placing a drop of topical anesthetic such as proparacaine or lidocaine on 
the eye to be inserted. Then adding lidocaine gel on a cotton- tipped swab 
and placing the swab directly on the lower punctum of the eye for 5 seconds and wait a few minutes.  Past investigators have found this to be effective 
in numbing the area around the lower punctum 
3. Use slight finger traction  on the lower lid to expose and stabilize the punctum 
4. Begin with the smallest gauge tip (0.5, 0.6, 0.7) of the Coroneo gage  
5. Gently insert the tip of the gauge in to the punctum vertically  
6. Once the horizontal canaliculus has been reached,  if necessary, gently turn the instrument 
horizontally to continue inserting past the vertical canaliculus  as you gently dilate 
7. Once the instrument is inserted past the third ring on the tip of the Coroneo gage , repeat  the 
above procedure using the larger end of the Coroneo gauge (0.8, 0.9, 1.0) 
8. The punctum must be dilated to at least 1.0 mm . Once the punctum is dilated to 1.0 mm, 
leave dilator in place for 20 to 30 seconds to allow the sphincter to fully relax. During 
this time  prepare the PPDS to be inserted . 
NOTE : For small puncta, hold and rotate the dilator in the punctum and canaliculus 
for as long as required to achieve dilation to 1.0 mm. This may take some considerable time (1 -2 minutes). Dilation may require very firm pressure 
however; care must be taken NOT to apply excessive force to dilate the 
punctum . Add more anesthesia if needed.  
Refer to Appendix G  for detailed procedure for inserting the PPDS 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  74 Mati Therapeutics Inc. - CONFIDENTIAL  
  
Appendix G  
PROCEDURES FOR INSERTION  OF A PPDS  
The procedure for inserting Mati’s PPDS punctal plug is similar to those for commercial plugs.  
Mati’s PPDS is for single -patient use only .  
NOTE:   Do not use a lubricant when inserting the plug , this may facilitate inadvertent 
plug intrusion below the punctal opening. 
1. Once the punctum has been dilated to 1.0 mm, leave the dilator in place  for 20 to 30 seconds 
to allow the sphincter to fully relax. During this time prepare the PPDS to be insert ed by 
removing the foil laminate lid  and release the pre-loaded PPDS from the  preformed rigid 
tray 
2. Remove the dilator from the punctum and immediately attempt to insert the PPDS before the 
sphincter starts to close  
3. Use slight finger traction on the lower lid to expose and stabilize the punctum , and position 
the plug end of the insertion instrument over the study subject’s punctum 
4. Insert the plug, coming straight down perpendicular to the punctum until the cap of the plug 
is flush with the lid margin  
5. Once the plug is in the proper position, release the lower lid and press the release button and 
pull the insertion instrument away from the study subject’s punctum 
After insertion, the punctal opening should be visually inspected using a slit -lamp to confirm the 
retention and proper placement of the PPDS, with the cap still visible. The position of the PPDS 
may be adjusted with forceps or the tip of the inserter if necessary. However, if unable to position the cap of the plug flush with the lid margin , the plug should be removed and the punctum re -
dilated or dilated to a larger diameter. Placement of the plug can then be re -attempted. Multiple 
attempts are sometimes necessary  
NOTE : Removal of a properly positioned PPDS immediately after insertion may result in 
the cap of the plug being torn off. Investigator should wait until the following day 
to allow the punctal sphincter to adjust (relax) before attempting to remove a PPDS. If the plug tears or separates, report this as a technical complaint ( Section  
8.6.3). Retain all removed or damaged PPDS for accountability of investigational supplies.   
If the PPDS cannot be inserted after a few attempts with gentle dilation, the subject is not eligible for the study.   
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  75 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendi x H 
PROCEDURES FOR REMOVAL OF A PPDS  
The PPDS should be removed from the study subject’s lower puncta using sterile ophthalmic 
forceps, such as Castroviejo Suture forceps ( Figure 6) or similar toothed forceps. When removing 
a PPDS, if necessary, a drop of anesthetic may be administered.   
Figure 6 
Castroviejo Corneal Suturing Forceps 1x2 0.12mm 90° Straight, Titanium  
  
  
a. Care must be taken not to grasp the outermost edge 
of the cap on the punctal plug as this may cause the 
cap to tear and separate, making it difficult to 
remove the plug from the canaliculus and/or 
causing plug intrusion 
b. The teeth of the forceps should NOT  be used to 
grasp the neck of the PPDS, but are placed on the 
far side s of the plug with the blades straddling the 
neck . The teeth of the forceps are  used instead to 
prevent the blades of the forceps from sliding off 
the neck.  Grasping the neck of the plug with the 
teeth may fracture or tear the plug Figure  7 
Punctal Plug Delivery System  
(L-shape Model L67)  
`  
c. The first motion to remove the plug should be towards the medial canthus (not up or 
temporally), which is necessary to disengage the heel of the plug, pulling the plug out with 
a tugging motion towards the medial canthus  
NOTE:  Care must be taken not to grasp the outermost edge of the cap on the punctal 
plug, as this may cause the cap to tear and separate, making it difficult to remove the plug from the canaliculus and/or causing plug intrusion. 
If the cap becomes separated, removal of the plug can be attempted using toothed 0.12 forceps 
(0.12 Castroviejo forceps or similar) by grasping the neck of the plug through the punctum. If this is not possible, and it does not appear that the plug will lodge in the canal, and only if the investigator feels comfortable doing so, he or she may attempt to irrigate the canal until the plug flushes out of the nasolacrimal duct.  

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  76 Mati Therapeutics Inc. - CONFIDENTIAL  
 NOTE : A PPDS is larger than commercially available silicone plugs and may become 
lodged in the canal more easily. Clinical judgment should be exercised when 
proceeding. Referral to tertiary care is advised in cases where the plug cannot be 
retrieved by massaging/milking through the punctal opening or by irrigation. Plug intrusion at removal, or spontaneous migration of a PPDS beyond the punctal 
opening such that massage, irrigation, or punctoplasty is required to remove it 
should be recorded as an AE. 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  77 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix  I 
TRAVATAN® (travoprost ophthalmic solution) 0.004% Sterile  
DESCRIPTION  
TRAVAT AN® (travoprost ophthalmic solution) 0.004% Sterile DESCRIPTION Travoprost is a 
synthetic prostaglandin F2α analogue. Its chemical name is isopropyl (Z)-7[(1R,2R,3R,5S)-3,5-
dihydroxy-2-[(1E,3R)-3-hydroxy-4- [(α,α,α- trifluoro -m-tolyl)oxy] -lbutenyl]cyclopent yl]-5-
heptenoate. It has a molecular formula of C26H35F3O6 and a molecular weight of 500.56.  The chemical structure of travoprost is:  
 
Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.  
TRAVATAN® Ophthalmic Solution 0.004% is supplied as sterile, buffered aqueous solution of 
travoprost with a pH of approximately 6.0 and an osmolality of approximately 290 mOsmol/kg.  
Each mL of TRAVATAN® 0.004% contains 40 ug travoprost. Benzalkonium chloride 0.015% is 
added as a preservative. Inactive Ingredients are: polyoxyl 40 hydrogenate d castor oil, 
tromethamine, boric acid, mannitol, edetate disodium, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water. 
CLINICAL PHARMACOLOGY  
Mechanism of Action  
Travoprost free acid is a selective FP prostanoid receptor agonist which is believed to reduce 
intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.  
Pharmacokinetics/Pharmacodynamics  
Absorption:  Travoprost is absorbed through the cornea and is hydrolyzed to the ac tive free acid. 
Data from four multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that 
plasma concentrations of the free acid are below 0.01 ng/ml (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N=38), 
the mean plasma Cmax was 0.018 ± 007 ng/ml (ranged 0.01 to 0.052 ng/mL) and was reached 

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  78 Mati Therapeutics Inc. - CONFIDENTIAL  
 within 30 minutes.  From these studies, travoprost is estimated to have a plasma half -life of 45 
minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating 
steady -state was reached early and that there was no significant accumulation.  
Metabolism: Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biolog ically active free acid. Systemically, travoprost free acid is metabolized to inactive 
metabolites via beta -oxidation of the α (carboxylic acid) chain to give the 1,2- dinor and 1,2,3,4-
tetranor analogs, via oxidation of the 15 -hydroxyl moiety, as well as v ia reduction of the 13,14-
double bond.  
Elimination: The elimination of travoprost free acid from plasma was rapid and levels were 
generally below the limit of quantification within one hour after dosing.  The terminal elimination half-life of travoprost free acid was estimated from fourteen subjects and ranged from 17 minutes 
to 86 minutes with the mean half -life of 45 minutes.  Less than 2% of the topical ocular dose of 
travoprost was excreted in the urine within 4 hours as the travoprost free acid.  
Clinical Studies  
In clinical studies, patients with open -angle glaucoma or ocular hypertension and baseline pressure 
of 25 - 27 mmHg who were treated with TRAVATAN® Ophthalmic Solution 0.004% dosed once -
daily in the evening demonstrated 7 - 8 mmHg reductions in intraocular pressure. In subgroup 
analyses of these studies, mean IOP reduction in black patients was up to 1.8 mmHg greater than 
in non- black patients. It is not known at this time whether this difference is attributed to race or to 
heavily pigmented irides. In a multi -center, randomized, controlled trial, patients with mean 
baseline intraocular pressure of 24 - 26 mmHg on TIMOPTIC* 0.5% BID who were treated with 
TRAVATAN® 0.004% dosed QD adjunctively to TIMOPTIC* 0.5% BID demonstrated 6 - 7 
mmHg reductions in intraocular pressure.  
TRAVATAN® has been studied in patients with hepatic impairment and also in patients with renal 
impairment.  No clinically relevant changes in hematology, blood chemistry, urinalysis laboratory data were observed in these pati ents.  
INDICATIONS AND USAGE  
TRAVATAN® Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open- angle glaucoma or ocular hypertension who are intolerant of other intraocular 
pressure lowering medications or  insufficiently responsive (failed to achieve target IOP 
determined after multiple measurements over time) to another intraocular pressure lowering medication.  
 
 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  79 Mati Therapeutics Inc. - CONFIDENTIAL  
 CONTRAINDICATIONS  
TRAVATAN® is contraindicated in patients with hypersensitivity to travoprost, benzalkonium 
chloride or any other ingredients in this product.  
WARNINGS  
TRAVATAN® has been reported to cause changes to pigmented tissues. The most frequently 
reported changes have been increased pigmentation of the iris and periorbital tissue (eyel id) 
and increased pigmentation and growth of eyelashes. These changes may be permanent . 
TRAVATAN® may gradually change eye color, increasing the amount of brown pigmentation in the iris by increasing the number of melanosomes (pigment granules) in melanocytes. The long -
term effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of pigment granules to other areas of the eye are currently unknown. The change in iris color occurs slowly and may not be noticeable for months to years. Patients should be informed of the possibility of iris color change.  
Eyelid skin darkening has been reported in association with the use of TRAVATAN®.  TRAVATAN® may gradually change eyelashes in the treated eye; these changes inclu de 
increased length, thickness, pigmentation, and/or number of lashes.  Patients who are expected to receive treatment in only one eye should be informed about the 
potential for increased brown pigmentation of the iris, periorbital and/or eyelid tissue, and eyelashes in the treated eye and thus heterochromia between the eyes. They should also be advised of the potential for a disparity between the eyes in length, thickness, and/or number of eyelashes. 
PRECAUTIONS  
General  
There have been reports of bacterial keratitis associated with the use of multiple -dose containers 
of topical ophthalmic products. These containers had been inadvertently contaminated by patients 
who, in most cases, had a concurrent cornea1 disease or a disruption of the epithelial surface (see 
Information for Patients).  
Patients may slowly develop increased brown pigmentation of the iris. This change may not be noticeable for months to years (see Warnings). Iris pigmentation changes may be more noticeable in patients with mixed colored irides, i.e., blue -brown, grey -brown, yellow -brown, and green-
brown; however, it has also been observed in patients with brown eyes. The color change is believed to be due to increased melanin content in the stromal melanocytes of the iris. The exact mechanism of action is unknown at this time. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  80 Mati Therapeutics Inc. - CONFIDENTIAL  
 become more brownish. Until more information about increased brown pigmentation is available, 
patients should be examined regularly and, depending on the situation, treatment may be stopped if increased pigmentation ensues.  
TRAVATAN® should be used with caution in patients with a history of intraocular inflammation 
(iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.  
Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F
2α analogues. These reports have mainly occurred in aphakic patients, 
pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. TRAVATAN® should be used with caution in these patients.  
TRAVATAN® has not been evaluated for the treatment of angle closure, inflammatory or 
neovascular glaucoma.  
TRAVATAN® Ophthalmic Solution should not be administered while wearing contact lenses. 
Patients should be advised that TRAVATAN® contains benzalkonium chloride which may be 
absorbed by contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of TRAVATAN®.  
Information for Patients  
Patients should be advised concerning all the information contained in the Warnings and 
Precautions sections.  
Patients should also be instructed to avoid allowing the tip of the dispensing container to contact 
the eye or surrounding structures because thi s could cause the tip to become contaminated by 
common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.  
Patients also should be advised that if they develop an intercurrent ocular condition (e.g., trauma, 
or infection) or have ocular surgery, they should immediately seek the physician’s advice 
concerning the continued use of the multi-dose container.  
Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and 
lid reactions, they should immediately seek his/her physician’s advice.  
If more than one topical ophthalmic drug is being used, the drugs should be administered at least 
five (5) minutes apart.  
Carcinogenesis, Mut agenesis, Impairment of Fertility    
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  81 Mati Therapeutics Inc. - CONFIDENTIAL  
 Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 
µg/kg/day did not show any evidence of carcinogenic potential.  However, at 100 µg/kg/day, male 
rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in 
the mouse study.  The high dose (100 µg/kg) corresponds to exposure levels over 400 times the human exposure at the maximum recommended human ocular dose (MRHOD) of 0.04 µg/kg, 
based on plasma act ive drug levels. Travoprost was not mutagenic in the Ames test, mouse 
micronucleus test and rat chromosome aberration assay. A slight increase in the mutant frequency 
was observed in one of two mouse lymphoma assays in the presence of rat S -9 activation en zymes.  
Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 10 ug/kg/day [250 times the maximum recommended human ocular dose of 0.04 ug/kg/day on a ug/kg basis (MRHOD)]. At 10 ug/kg/day, the mean number  of corpora lutea was reduced, 
and the postimplantation losses were increased. These effects were not observed at 3 ug/kg/day (75 times the MRHOD).  
Pregnancy: Teratogenic Effects  
Pregnancy Category: C Travoprost was teratogenic in rats, at an intravenous  (IV) dose up to 10 
ug/kg/day (250 times the MRHOD), evidenced by an increase in the incidence of skeletal 
malformations as well as external and visceral malformations, such as fused sternebrae, domed 
head and hydrocephaly. Travoprost was not teratogenic in rats at IV doses up to 3 ug/kg/day (75 
times the MRHOD), and in mice at subcutaneous doses up to 1.0 ug/kg/day (25 times the MRHOD). Travoprost produced an increase in postimplantation losses and a decrease in fetal 
viability in rats at IV doses > 3 ug/k g/day (75 times the MRHOD) and in mice at subcutaneous 
doses > 0.3 ug/kg/day (7.5 times the MRHOD). 
In the offspring of female rats that received travoprost subcutaneously from Day 7 of pregnancy 
to lactation Day 21 at the doses of ≥ 0.12 ug/kg/day (3 time s the MRHOD), the incidence of 
postnatal mortality was increased, and neonatal body weight gain was decreased. Neonatal 
development was also affected, evidenced by delayed eye opening, pinna detachment and preputial 
separation, and by decreased motor activ ity.  
There are no adequate and well -controlled studies in pregnant women.  TRAVATAN® should be 
used during pregnancy only if the potential benefit justifies the potential risk to the fetus.    
Nursing Mothers  
A study in lactating rats demonstrated that radiolabeled travoprost and/or its metabolites were 
excreted in milk. It is not known whether this drug or its metabolites are excreted in human milk. 
Because many drugs are excreted in human milk, caution should be exercised when 
TRAVATAN® is administered to a nursing woman.  
Pediatric Use  
Safety and effectiveness in pediatric patients have not been established.   
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  82 Mati Therapeutics Inc. - CONFIDENTIAL  
 Geriatric Use  
No overall differences in safety or effectiveness have been observed between elderly and other 
adult patients.  
ADVERSE REACTIONS   
The most common ocular adverse event observed in controlled clinical studies with 
TRAVATAN® 0.004% was ocular hyperemia which was reported in 35 to 50% of patients. Approximately 3% of patients discontinued therapy due to conjunctival hyperemia.  
Ocular adverse events reported at an incidence of 5 to 10% included decreased visual acuity, eye 
discomfort, foreign body sensation, pain, and pruritus.  
Ocular adverse events reported at an incidence of 1 to 4% included, abnormal vision, blepharitis, 
blurred vision, cataract, cells, conjunctivitis, dry eye, eye disorder, flare, iris discoloration, 
keratitis, lid margin crusting, photophobia, subconjunctival hemorrhage, and tearing.  
Nonocular adverse events reported at a rate of 1 to 5% were accidental inj ury, angina pectoris, 
anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold syndrome, depression, 
dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infection.    
DOSAGE AND ADMINISTRATION  
The recommended dosage is one drop in the affected eye(s) once -daily in the evening. The dosage 
of TRAVATAN® should not exceed once -daily since it has been shown that more frequent 
administration may decrease the intraocular pressure lowering effect. Reduction of intraocular 
pressure starts approximately 2 hours after administration, and the maximum effect is reached after 12 hours.  
TRAVATAN® may be used concomitantly wit h other topical ophthalmic drug products to lower 
intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be 
administered at least five (5) minutes apart.  
HOW SUPPLIED  
TRAVATAN® (travoprost ophthalmic solution) 0.004% is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 mg/mL) supplied in Alcon’s oval DROP -TAINER® package 
system. TRAVATAN® is supplied as a 2.5 mL solution in a 4 mL and a 5 mL solution in a 7.5 mL natural polypropylene dispenser bottle with a natural polypropylene dropper tip and a turquoise polypropylene overcap. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC 0065 -0266- 25, 2.5 mL fill NDC 0065-0266- 17, 2 units, 2.5 mL fi ll 
each NDC 0065-0266-34, 5 mL fill   
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  83 Mati Therapeutics Inc. - CONFIDENTIAL  
 Storage  
Store at 2° - 25°C (36° - 77°F).  Rx Only  
Rx Only  
U.S. Patent Nos. 5,631,287; 5,849,792; 5,889,052; 6,011,062, and 6,235,781.  
*TIMOPTIC is a registered trademark of Merck & Co., Inc.  
ALCON LOGO  
ALCON LABORATORIES, INC.   
Fort Worth, Texas 76134 USA  ©2004 Alcon, Inc. 
 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  84 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix J 
TRAVATAN Z®  PACKAGE INSERT  
FULL PRESCRIBING INFORMATION  
1 INDICATIONS AND USAGE  
TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of 
elevated intraocular pressure (IOP) in patients with open -angle glaucoma or ocular hypertension.  
2 DOSAGE AND ADMINISTRATION  
The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.  
Reduction of the IOP starts approximately 2 hours after the first administration with maximum 
effect reached after 12 hours.  
TRAVATAN Z may be used concomitantly with other topical ophthalmic drug products to lower 
IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.  
3 DOSAGE FORMS AND STRENGTHS  
Ophthalmic solution containing travoprost 0.04 mg/mL.  
4 CONTRAINDICATIONS  
None.  5 WARNINGS AND PRECAUTIONS  
5.1 Pigmentation  
Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most 
frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. The pigmentati on change is due to increased melanin content in the melanocytes rather than to an 
increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have 
been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long -term effects of increased pigmentation are 
not known.  
Iris color change may not be noticeable for several months to years. Typically, the brown 
pigmentation around the pupil spreads concentrically towards the periphery of the iris and the 
entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  85 Mati Therapeutics Inc. - CONFIDENTIAL  
 be affected by treatment. While treatment with TRAVATAN Z can be continued in patients who 
develop noticeably increased iris pigmentation, these patients should be examined regularly.  
5.2 Eyelash Changes  
TRAVATAN Z may gradually change eyelashes and vellus hair in the treated eye. These changes 
include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.  
5.3 Intraocular Inflammation  
TRAVATAN Z should be used with caution i n patients with active intraocular inflammation (e.g., 
uveitis) because the inflammation may be exacerbated.  
5.4 Macular Edema  Macular edema, including cystoid macular edema, has been reported during treatment with 
travoprost ophthalmic solution. TRAVATAN Z should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.  
5.5 Angle-closure, Inflammatory or Neovascular Glaucoma  
TRAVATAN Z has not been ev aluated for the treatment of angle -closure, inflammatory or 
neovascular glaucoma.  
5.6 Bacterial Keratitis  
There have been reports of bacterial keratitis associated with the use of multiple- dose containers 
of topical ophthalmic products. These containers had been inadvertently contaminated by patients 
who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.  
5.7 Use with Contact Lenses  
Contact lenses should be removed prior to instillation of TRAVATAN Z and may be reinserted 15 
minutes following its administration.  
6 ADVERSE REACTIONS  
6.1 Clinical Trials  
Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates obs erved in practice.  
The most common adverse reaction observed in controlled clinical trials with TRAVATAN and TRAVATAN Z was ocular hyperemia, which was reported in 30% to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyper emia. Ocular adverse reactions reported 
at an incidence of 5% to 10% in these clinical trials included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus.  
Ocular adverse reactions reported at an incidence of 1% to 4% in cl inical trials with TRAVATAN 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  86 Mati Therapeutics Inc. - CONFIDENTIAL  
 or TRAVATAN Z included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, 
corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing.  
Non-ocular adverse reactions reported at an incidence of 1% to 5% in these clinical studies were 
allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu 
syndrome, depression, dyspepsia, g astrointestinal disorder, headache, hypercholesterolemia, 
hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infections.  
6.2 Postmarketing Experience  
Additional adverse reactions have been identified during post approval use of TRAVATAN or 
TRAVATAN Z in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to TRAVATAN or TRAVATAN Z, or a combination of these factors, include: arrhythmia, vomiting, epistaxis, tachycardia, and insomnia.  
In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening 
of the eyelid sulcus have been observed.  
8 USE IN SPECIFIC POPULATIONS  
8.1 Pregnancy  
Risk Summary  
There are no adequate and well -controlled studies in pregnant women to inform a drug -associated 
risk.  
In animal reproduction studies, subcutaneous (SC) administration of travoprost to pregnant mice 
and rats throughout the period of organogenesis produced embryo -fetal lethality, spontaneous 
abortion, and premature delivery at potentially clinically relevant dos es.  
Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not 
always predictive of human response, TRAVATAN Z should be administered during pregnancy only if the potential benefit justifies the potential risk to the  fetus.  
The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clini cally recognized pregnancies.  
Data  
Animal Data  
An embryo -fetal study was conducted in pregnant rats administered travoprost once daily by SC 
injection from gestation day (GD) 6 to 18, to target the period of organogenesis. At 10 mcg/kg (60 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  87 Mati Therapeutics Inc. - CONFIDENTIAL  
 times the max imum recommended human ocular dose [MRHOD], based on estimated plasma 
Cmax), travoprost was teratogenic in rats, evidenced by an increase in the incidence of skeletal 
malformations as well as external and visceral malformations, including fused sternebrae,  domed 
head and hydrocephaly. Travoprost caused post -implantation loss at 10 mcg/kg. The no observed 
adverse effect level (NOAEL) for post -implantation loss was 3 mcg/kg (18 times the MRHOD, 
based on estimated plasma Cmax). The maternal NOAEL was 10 mcg/kg .  
An embryo-fetal study was conducted in pregnant mice administered travoprost once daily by SC injection from GD 6 to 11, to target the period of organogenesis. At 1 mcg/kg (6 times the MRHOD, based on estimated plasma Cmax), travoprost caused postimplantation loss and decreased fetal weight. The no observed adverse effect level (NOAEL) for malformations was 0.3 mcg/kg (2 times the MRHOD, based on estimated plasma Cmax). The maternal NOAEL was 1 mcg/kg.  
Pre/postnatal studies were conducted in rats administered travoprost once daily by subcutaneous injection from GD 7 (early embryonic period) to postnatal Day 21 (end of lactation period). At doses of greater than or equal to 0.12 mcg/kg/day (0.7 times the MRHOD, based on estimated plasma Cmax), adverse pre gnancy outcomes (embryo -fetal lethality, abortion, and early delivery), 
low-birth weight and developmental delays were observed. The NOAEL for adverse pregnancy 
outcomes, low -birth weight and developmental delay was 0.1 mcg/kg (0.6 times the MHROD, 
based o n estimated plasma Cmax). The NOAEL for maternal toxicity was 0.72 mcg/kg (4 times 
the MHROD, based on estimated plasma Cmax).  
8.2 Lactation  
Risk Summary  
There are no data on the effects of travoprost on the breastfed child or milk production. It is not 
known if travoprost is present in human milk following ophthalmic administration. A study in lactating rats demonstrated that radio -labeled travoprost and/or its metabolites were excreted in 
milk following subcutaneous administration.  
The developmental and health benefits of breastfeeding should be considered along with the 
mother’s clinical need for TRAVATAN Z and any potential adverse effects on the breast -fed child 
from TRAVATAN Z.  
8.4 Pediatric Use  
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.  
8.5 Geriatric Use  
No overall clinical differences in safety or effectiveness have been observed between elderly and 
other adult patients.  
8.6 Hepatic and Renal Impairment  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  88 Mati Therapeutics Inc. - CONFIDENTIAL  
 Travoprost ophthalmic solution 0.004% has been studied in patients with hepatic impairment and 
also in patients with renal impairment. No clinically relevant changes in hematology, blood chemistry, or urinalysis laboratory data were observed in these patients.  
11 DESCRIPTION  
Travoprost is a synthetic prostaglandin F analog. Its chemical name is [1R -
[1α(Z),2β(1E,3R*),3α,5α]]-7-[3,5- Dihydroxy -2-[3-hydroxy -4-[3-(trifluoromethyl) phenoxy] -1-
butenyl]cyclopentyl]-5- heptenoic acid, 1 - methylethylester. It has a molecular formula of 
C26H35F3O6 and a molecular weight of 500.55 g/mol. The chemical structure of travoprost is: 
 
Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, 
octanol, and chloroform. It is practically insoluble in water.  
TRAVATAN Z is supplied as sterile, buffered aqueous solution of travoprost with a pH of 
approximately 5.7 and an osmolality of approximately 290 mOsmol/kg.  
TRAVATAN Z contains Active: travoprost 0.04 mg/mL; Inactives: polyoxyl 40 hydrogenated 
castor oil, sofZia® (boric acid, propylene glycol, sorbitol, zinc chloride), sodium hydroxide and/ or 
hydrochloric acid (to adjust pH), and purified water, USP. Preserved in the bottle with an ionic buffered system, sofZia®.  
12 CLINICAL PHARMACOLOGY  
12.1 Mechanism of Action  
Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which 
is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.  
12.3 Pharmacokinetics  
Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from 4 
multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that plasma 
concentrations of the free acid are below 0.01 ng/mL (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N = 38), the mean plasma Cmax was 0.018 ± 0.007 ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached 

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  89 Mati Therapeutics Inc. - CONFIDENTIAL  
 within 30 minutes. From these studies, travoprost is estimated to have a plasma half -life of 45 
minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating 
steady -state was reached early and that there was no significant accumulation.  
Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically , travoprost free acid is metabolized to inactive metabolites via beta -
oxidation of the α (carboxylic acid) chain to give the 1,2- dinor and 1,2,3,4 -tetranor analogs, via 
oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13, 14 double bond.  
The elimination of travoprost free acid from plasma was rapid and levels were generally below the 
limit of quantification within one hour after dosing. The terminal elimination half -life of travoprost 
free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the 
mean half -life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted 
in the urine within 4 hours as the travoprost free acid.  
13 NONCLINICAL TOXICOLOGY  
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility   
Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 
mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, 
male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100 mcg/kg) corresponds to exposure levels 326 times (mouse) and 547 times (rat) the human exposure at the MRHOD of 0.04 mcg/kg, based on estimated plasma Cmax for active travoprost free acid.  
Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the presence of rat S-9 activation enzymes.  
Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses 
up to 3 mcg/kg/day (18 times the MRHOD based on estimated plasma Cmax). At 10 mcg/kg/day (60 times the MRHOD, based on estimated plasma  Cmax), the mean number of corpora lutea was 
reduced, and the post- implantation losses were increased.  
14 CLINICAL STUDIES  
In clinical studies, patients with open -angle glaucoma or ocular hypertension and baseline pressure 
of 25 to 27 mmHg, who were treated with TRAVATAN or TRAVATAN Z dosed once daily in the evening, demonstrated 7 to 8 mmHg reductions in IOP. In sub- group analyses of these studies, 
mean IOP reduction in black patients was up to 1.8 mmHg greater than in non- black patients. It is 
not known at this time whether this difference is attributed to race or to heavily pigmented irides.  
In a multi- center, randomized, controlled trial, patients with mean baseline IOP of 24 to 26 mmHg 
on TIMOPTIC** 0.5% twice daily who were treated with TRAVATAN dosed daily adjunctively to TIMOPTIC** 0.5% twice daily demonstrated 6 to 7 mmHg reductions in IOP.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  90 Mati Therapeutics Inc. - CONFIDENTIAL  
 16 HOW SUPPLIED/STORAGE AND HANDLING  
TRAVATAN Z is a sterile, isotonic, buffered, preserved, aqueous solution of travoprost (0.04 
mg/mL).  
TRAVATAN Z is supplied as a 2.5 mL solution in a 4 mL and a 5 mL solution in a 7.5 mL oval natural polypropylene dispenser bottle with a natural polypropylene dropper tip and a turquoise polypropylene or high-density  polyethylene overcap. Tamper evidence i s provided with a shrink 
band around the closure and neck area of the package.  
2.5 mL fill NDC 0065-0260-25  
5 mL fill  NDC 0065-0260-05  
Storage:   Store at 2°C to 25°C (36°F to 77°F).  
After opening, TRAVATAN Z can be used until the expiration date on the bottle.  
17 PATIENT COUNSELING INFORMATION  
Potential for Pigmentation  
Advise the patient about the potential for increased brown pigmentation of the iris, which may be 
permanent. Inform the patient about the possibility of eyelid skin darkening, which m ay be 
reversible after discontinuation of TRAVATAN Z [ see Warnings and Precautions (5.1) ].  
Potential for Eyelash Changes  
Inform the patient about the possibility of eyelash and vellus hair changes in the treated eye during treatment with TRAVATAN Z. Thes e changes may result in a disparity between eyes in length, 
thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment [ see Warnings and 
Precaut ions (5.2) ].  
Handling the Container  
Instruct the patient to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent 
loss of vision may result from using contaminated solutions [ see Warnings and Precautions (5.6) ].  
When to Seek Physician Advice  
Advise the patient that if they develop an intercur rent ocular condition (e.g., trauma or infection), 
have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of TRAVATAN Z [ see Warnings and Precautions (5.3, 5.4, 5.5) ].  
Use with Contact Lenses  
Contact lenses should be removed prior to instillation of TRAVATAN Z and may be reinserted 15 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  91 Mati Therapeutics Inc. - CONFIDENTIAL  
 minutes following its administration [ see Warnings and Precautions (5.7) ].  
Use with Other Ophthalmic Drugs  
If more than one topical ophthalmic drug is being used, the drugs should be administered at least 
5 minutes between applications.  
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  92 Mati Therapeutics Inc. - CONFIDENTIAL  
 TIMOPTIC** is a registered trademark of Merck & Co., Inc.  
Distributed by:  
Novartis Pharmaceuticals Corpo ration  
East Hanover, New Jersey 07936  © Novartis  T2020-40 
  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  93 Mati Therapeutics Inc. - CONFIDENTIAL  
 Appendix K 
IZBA® PACKAGE INSERT  
FULL PRESCRIBING INFORMATION 
1 INDICATIONS AND USAGE  
IZBA (travoprost ophthalmic solution) 0.003% is indicated for the reduction of elevated 
intraocular pressure in patients with open- angle glaucoma or ocular hypertension.  
2 DOSAGE AND ADMINISTRATION  
The recommended dosage is one drop in the affected eye(s) once daily in the evening. IZBA 
(travoprost ophthalmic solution) 0.003% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the 
intraocular pressure lowering effe ct.  
Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.  
IZBA may be used concomitantly with other topical ophthalmic drug products to lower intraocular 
pressure. If  more than one topical ophthalmic drug is being used, the drugs should be administered 
at least five (5) minutes apart.  
3 DOSAGE FORMS AND STRENGTHS  
Ophthalmic solution containing travoprost 0.03 mg/mL.  
4 CONTRAINDICATIONS  
None  5 WARNINGS AND PRECAUTIONS  
5.1 Pigmentation 
Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most 
frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is  likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have 
been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long -term ef fects of increased pigmentation are 
not known.  
Iris color change may not be noticeable for several months to years. Typically, the brown 
pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of  the iris become more brownish. Neither nevi nor freckles of the iris appear to 
be affected by treatment. While treatment with IZBA (travoprost ophthalmic solution) 0.003% can be continued in patients who develop noticeably increased iris pigmentation, these patients should 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  94 Mati Therapeutics Inc. - CONFIDENTIAL  
 be examined regularly. (See Patient Counseling Information, 17.1). 
5.2 Eyelash Changes  
IZBA may gradually change eyelashes and vellus hair in the treated eye. These changes include 
increased length, thickness, and number of lashes. Eyel ash changes are usually reversible upon 
discontinuation of treatment.  
5.3 Intraocular Inflammation  
IZBA should be used with caution in patients with active intraocular inflammation (e.g., uveitis) 
because the inflammation may be exacerbated.  
5.4 Macular Edema  
Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. IZBA should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.  
5.5 Bacterial Keratitis  
There have been reports of bacterial keratitis associated with the use of multiple- dose containers 
of topical ophthalmic products. These containers had been inadvertently contaminated b y patients 
who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface (See Patient Counseling Information, 17.3).  
5.6 Use with Contact Lenses  
Contact lenses should be removed prior to instillation of IZBA and may be reinserted 15 minutes 
following its administration.  
6 ADVERSE REACTIONS  
6.1 Clinical Studies Experience  
 Because clinical studies are conducted under widely varying conditions, adve rse reaction rates 
observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.  
Different methodologies were used to collect adverse reactions during the development of 
travoprost. The most common adverse reaction observed in controlled clinical studies with travoprost 0.004% was ocular hyperemia. Ocular hyperemia was reported in 30 to 50% of patients by physician rating the severity of patient’s post treatment ocular hyperemia compared to 
standardized reference photographs and/or patients who discontinued therapy due to ocular hyperemia.  
In a 3-month clinical trial involving 442 patients exposed to IZBA (travoprost ophthalmic solution, 
0.003%) and 422 control patients exposed to travoprost ophthalmic solution, 0.004%, the most common adverse drug reaction was ocular hyperemia. This was reported in 12% of patients treated 
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  95 Mati Therapeutics Inc. - CONFIDENTIAL  
 with IZBA based on clinical observations and/or patient complaints. One patient (0.2%) 
discontinued treatment with IZBA due to ocular hyperemia. Rates observed in the control patients were comparable.   
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  96 Mati Therapeutics Inc. - CONFIDENTIAL  
 Ocular adverse reactions reported in clinical studies with travoprost ophthalmic solutions including 
IZBA at an incidence of 5% to 10% included decreased visual acuity, eye discomfort, foreign body 
sensation, pain and pruritus. Ocular adverse reactions reported at an incidence of 1 to 4% included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris 
discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage and tearing.  
Nonocular adverse reactions reported at an incidence of 1 to 5% in these clinical studies were 
allergy, angina pectoris , anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu 
syndrome, depression, dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary inc ontinence and 
urinary tract infections.  
In post marketing  use with prostaglandin analogs, periorbital and lid changes including deepening 
of the eyelid sulcus have been observed.  
8 USE IN SPECIFIC POPULATIONS  
8.1 Pregnancy  
Pregnancy Category C  
There are no adequate and well -controlled studies of IZBA (travoprost ophthalmic solution 
0.003%) administration in pregnant women. Malformations were observed in rats at doses that 
were 1500 times higher the maximum recommended human ocular dose (MRHOD) based on estimated Cmax values for the active free acid. Embryo lethality and decreased fetal/neonate viability were observed in mice at subcutaneous doses 9- fold higher than the MRHOD based on 
estimated Cmax for the active free acid. IZBA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
Travoprost was teratogenic in rats, at an intravenous (IV) dose up to 10 mcg/kg/day (1500 times the MRHOD, evidenced by an increase in the incidence of skeletal malformations  as well as 
external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. Travoprost did not produce malformations in rats at IV doses up to 3 mcg/kg/day (470 times the MRHOD), or in mice at subcutaneous doses up to 1 mcg/kg/day (9 times the MRHOD). Travoprost produced an increase in post -implantation losses and a decrease in fetal viability in rats at IV doses 
of 10 mcg/kg/day (1500 times the MRHOD) and in mice at subcutaneous doses of 1 mcg/kg/day (9 times the MRHOD).  
In the  offspring of female rats that received travoprost subcutaneously from Day 7 of pregnancy 
to lactation Day 21 at doses of ≥ 0.12 mcg/kg/day (3.2 times the MRHOD), the incidence of postnatal mortality was increased, and neonatal body weight gain was decreas ed. Neonatal 
development was also affected, evidenced by delayed eye opening, pinna detachment and preputial separation, and by decreased motor activity.  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  97 Mati Therapeutics Inc. - CONFIDENTIAL  
 8.3 Nursing Mothers  
A study in lactating rats demonstrated that radiolabeled travoprost and/or its metabolites were 
excreted in milk. It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IZBA is administered to a nursing woman.  
8.4 Pediatric Use  
Use in pediatric patients below the age of 16 years is not recommended because of potential safety 
concerns related to increased pigmentation following long term chronic use.  8.5 Geriatric Use  
No overall clinical differences in safety or effectiveness hav e been observed between elderly and 
other adult patients.  
11 DESCRIPTION Travoprost is a synthetic prostaglandin F2α analog. Its chemical name is [1R-
[1 (Z),2 (1E,3R*),3α ,5 α]]-7-[3,5- Dihydroxy -2-[3- hydroxy -4-[3-(trifluoromethyl) phenoxy] -1- 
butenyl]cyc lopentyl]-5- heptenoic acid, 1 -methylethylester. It has a molecular formula of 
C26H35F3O6 and a molecular weight of 500.55. The chemical structure of travoprost is: 
 
Travoprost is a clear, colorless to slightly yellow oil that is very soluble in acetonitrile, methanol, octanol, and chloroform. It is practically insoluble in water.  
IZBA (travoprost ophthalmic solution) 0.003% is supplied as sterile, isotonic, buffered aqueous 
solution of travoprost with a pH of approximately 6.8 and an osmolality of approximately 290 
mOsmol/kg.  
IZBA contains Active: travoprost 0.03 mg/mL; Preservative: POLYQUAD® (polyquaternium -1) 
0.01mg/mL; Inactives: boric acid, mannitol, polyoxyethylene 40 hydrogenated castor oil, propylene glycol, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water, USP.  
12 CLINICAL PHARMACOLOGY  
12.1 Mechanism of Action  
Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is 
believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism 

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  98 Mati Therapeutics Inc. - CONFIDENTIAL  
 of action is unknown at this time. 
12.3 Pharmacokinetics  
Travoprost is absorbed through the cornea and is hydroly zed to the active free acid. Data from four 
multiple dose pharmacokinetic studies using travoprost ophthalmic solution, 0.004% (totaling 107 
subjects) have shown that plasma concentrations of the free acid are below 0.01 ng/mL (the quantitation limit of th e assay) in two -thirds of the subjects. In those individuals with quantifiable 
plasma concentrations (N=38), the mean plasma Cmax was 0.018 ± 0.007 ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies, travoprost is esti mated to 
have a plasma half -life of 45 minutes. There was no difference in plasma concentrations between 
Days 1 and 7, indicating steady -state was reached early and that there was no significant 
accumulation.  
Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically 
active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta -
oxidation of the α(carboxylic acid) chain to give the 1,2- dinor and 1,2,3,4- tetranor analogs, via 
oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.  
The elimination of travoprost free acid from plasma was rapid and levels were generally below the 
limit of quantification within one hour after dosing. The terminal elimination half-life of travoprost 
free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the mean half -life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted 
in the urine within 4 hours as the travoprost free acid.  
13 NONCLINICAL TOXICOLOGY  
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility  
Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 
mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, 
male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100 mcg/kg) corresponds to exposure levels over 400 times (for the mouse) and 700 times (for the rat) of the human exposure at the maximum recommended human ocular dose (MRHOD) of 0.03 mcg/kg, based on estimated plasma Cmax for active free acid.  
Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the pres ence of rat S -9 activation enzymes.  
Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 10 mcg/kg/day (40 times the MRHOD based on estimated plasma Cmax for active free acid). At 10 mcg/kg/day, the mean  number of corpora lutea was reduced, and the post implantation  losses 
were increased. These effects were not observed at 3 mcg/kg/day (12 times the MRHOD).  
IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  99 Mati Therapeutics Inc. - CONFIDENTIAL  
 14 CLINICAL STUDIES  
A single clinical trial of 3 months duration was conducted to compare the IOP -lowering effect of 
IZBA (travoprost ophthalmic solution) 0.003% to TRAVATAN (travoprost ophthalmic solution) 
0.004%, with both dosed once daily in the evening in adult patients with open angle glaucoma or 
ocular hypertension. Patient age ranged from 21 to 92 years, with a mean age of 65 years. A total of 864 patients (IZBA, 442 patients; TRAVATAN, 422 patients) were enrolled, with 840 (97%) 
completing through Month 3.  
Analysis was based on the intent -to-treat (ITT) population defined as all patients who re ceived 
study drug and completed at least one scheduled on- therapy study visit.  
The least squares mean IOP (mmHg), the difference in mean IOP (IZBA minus TRAVATAN), 
and the 95% CI for the treatment difference in mean IOP at visit and time point are present ed in 
Table 1. The differences in the mean IOP at all visits and time points were within ±1 mmHg, 
demonstrating equivalence of IZBA to TRAVATAN in lowering intraocular pressure.  
Table 2 presents the mean IOP change from baseline at Week 2, Week 6, and at Month 3. IZBA 
demonstrated comparable IOP reductions at all on -therapy visits and time points; the mean IOP 
reduction from baseline in the IZBA group ranged from 7.1 to 8.2 mmHg and in the TRAVATAN 
group ranged from 7.1 to 8.4 mmHg. In both treatment groups, the greatest mean IOP reduction was observed at the 8 AM assessment time point.  
Table 1 Mean IOP (mmHg) by Treatment Group and Treatment Difference in Mean IOP 
 
SE = Standard Error; CI = Confidence Interval * Estimates for Week 2, Week 6, and Month 3 are based on least squares means 
derived from a statistical model that accounts for correlated IOP measurements within patient where site and 8 AM baseline IO P 
stratu m are in the model; estimates for Baseline visit at each time point are based on a two-sample  independent t -test procedure. 
**One subject had missing data at 8 AM at Week 6; one subject had missing data at 4 PM at Month 3.  

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  100 Mati Therapeutics Inc. - CONFIDENTIAL  
 Table 2. IOP Change from Baseline (mmHg)  
 
*One subject had missing data at 8 AM at Week 6; one subject had missing data at 4 PM at Month 3.  
16 HOW SUPPLIED/STORAGE AND HANDLING  
IZBA (travoprost ophthalmic solution) 0.003% is a sterile, isotonic, buffered, preserved, aqueous 
solution of travoprost (0.03 mg/mL) supplied in Alcon's oval DROP- TAINER® package system.  
IZBA is supplied as a 2.5 mL solution in a 4 mL bottle and a 5 mL solution in a 7.5 mL bottle. The 
dispenser bottles are made of polypropylene and fitted with a natural color polypropylene dropper 
tip and a turquoise polypropylene over cap . Tamper evidence is provided with a shrink band around 
the closure and neck area of the package.  
2.5 mL fill NDC 0065-0000-00  
5 mL fill NDC 0065-0000-00  Storage : Store at 2° - 25°C (36° - 77°F).  
17 PATIENT COUNSELING INFORMATION  
17.1 Potential for Pigmentation  
Advise patients about the potential for increased brown pigmentation of the iris, which may be 
permanent. Advise patients about the possibility of eyelid skin darkening, which may be  reversible 
after discontinuation of IZBA (travoprost ophthalmic solution 0.003%).  
17.2 Potential for Eyelash Changes  
Advise patients about the possibility of eyelash and vellus hair changes in the treated eye during 
treatment with IZBA. These changes ma y result in a disparity between eyes in length, thickness, 
pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.  
17.3 Handling the Container  
Instru ct patients to avoid allowing the tip of the dispensing container to contact the eye, 
surrounding structures, fingers, or any other surface in order to avoid contamination of the solution 
by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.    

IND 11430   Study Protocol TGLA -2021- 01 
Travoprost Evolute®, 166 µg, L67  
 
Version 3:  08 Apr 22  101 Mati Therapeutics Inc. - CONFIDENTIAL  
 17.4 When to Seek Physician Advice  
Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection), 
have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice  concerning the continued use of 
IZBA.  
17.5 Use with Contact Lenses  
Contact lenses should be removed prior to instillation of IZBA and may be reinserted 15 minutes 
following its administration.  
17.6 Use with Other Ophthalmic Drugs  
If more than one topical ophthalmic drug is being used, the drugs should be administered at least 
five (5) minutes between applications.  
Rx Only  
U.S. Patent Nos. 5,631,287; 5,849,792; 5,889,052; 6,011,062; 8,178,582  
ALCON®  
ALCON LABORATORIES, INC. Fort Worth, Texas 76134 U SA 
© 2006, 2010, 2011, 2012, 2013 Novartis  9007509-1111  PRINCIPAL DISPLAY PANEL  
NDC 0065-0000-00 Rx Only  IZBA (travoprost ophthalmic solution) 0.003%  
Alcon®                             2.5 mL 